Stockwinners Market Radar for April 04, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 311.3K shares of Nurix Therapeutics today

19:23 EDT BlackSky's new satellites began revenue-generating commercial operations - BlackSky announced that its"newest satellites successfully began revenue-generating commercial operations for customers, taking high-resolution images and creating analytics within a company record of 12 hours after launch. The company expanded its constellation from 12 to 14 high-resolution satellites following the successful RocketLab launch "Without Mission a Beat" on Saturday, April 2. This mission marks the fourth BlackSky satellite launch mission in the last four months."

18:06 EDT GitLab names Ashley Kramer chief marketing and strategy officer - GitLab announced that Ashley Kramer has joined the company as its Chief Marketing and Strategy Officer. "I am excited to welcome Ashley Kramer as CMSO and to have her at the helm of our marketing organization," said GitLab CEO and co-founder, Sid Sijbrandij. "I believe Ashley's mix of marketing, product, and technology leadership positions make her well suited to lead as GitLab enters into the next phase of market leadership." "As a former engineer, I am drawn to GitLab's unique ability to solve a deep developer pain point - streamlining the development process and bringing innovative ideas to customers in a quicker and more efficient way," said Kramer. "I am thrilled to join GitLab as Chief Marketing and Strategy Officer and look forward to contributing to GitLab's continued success." Kramer joins GitLab from Sisense, where she served as Chief Marketing Officer and Chief Product Officer and was responsible for leading the company's go-to-market and product strategy, brand awareness and revenue growth.

17:54 EDT Flotek regains compliance with NYSE continued listing standard - Flotek Industries announced it has received written notice from the New York Stock Exchange that it has regained compliance with the NYSE's continued listing standards. The notification is a result of the company's average closing price for the 30-trading days ended March 31, 2022 exceeding the NYSE's minimum requirement of $1.00 per share, based on a 30-trading day average. On December 10, 2021, the company reported it had received notice that from the NYSE that the average closing price of the company's shares of common stock was below $1.00 per share over a period of 30 consecutive trading days, which is below the requirement for continued listing on the NYSE. The company is no longer considered below the $1.00 per share continued listing criterion and the below compliance ".BC" indicator will be removed from the company's common shares.

17:34 EDT Fluidigm has been renamed Standard BioTools - Fluidigm (FLDM) announced the closing of the previously announced strategic capital infusion from life sciences investors Casdin Capital and Viking Global Investors. Fluidigm has been renamed Standard BioTools and its common stock is expected to begin trading on Nasdaq under the symbol "LAB" as of the open of market on April 6. Standard BioTools will focus on significantly advancing its mission to become an essential solutions partner to the life science industry focused on the highest growth areas of biological discovery and development.

17:31 EDT Lion Electric receives order for 50 all-electric school buses - Lion Electric announced that it has received an order for 50 all-electric LionC school buses from Autobus Campeau in the province of Quebec, with deliveries to begin by the first quarter of 2023. The new buses will be used on school routes in the Brownsburg-Chatham, Gatineau and Rigaud regions and are in addition to the LionC which Autobus Campeau has been operating in their school bus fleet since 2016.

17:29 EDT Block says former employee accessed Cash App Investing without permission - On April 4, Block announced that it recently determined that a former employee downloaded certain reports of its subsidiary Cash App Investing LLC on December 10, 2021 that contained some U.S. customer information. While this employee had regular access to these reports as part of their past job responsibilities, in this instance these reports were accessed without permission after their employment ended. The information in the reports included full name and brokerage account number, and for some customers also included brokerage portfolio value, brokerage portfolio holdings and/or stock trading activity for one trading day. The reports did not include usernames or passwords, Social Security numbers, date of birth, payment card information, addresses, bank account information, or any other personally identifiable information. They also did not include any security code, access code, or password used to access Cash App accounts. Other Cash App products and features and customers outside of the United States were not impacted. Upon discovery, the company and its outside counsel launched an investigation with the help of a leading forensics firm. Cash App Investing is contacting approximately 8.2M current and former customers to provide them with information about this incident and sharing resources with them to answer their questions. The company is also notifying the applicable regulatory authorities and has notified law enforcement. The company takes the security of information belonging to its customers very seriously and continues to review and strengthen administrative and technical safeguards to protect the information of its customers. Future costs associated with this incident are difficult to predict. Although the company has not yet completed its investigation of the incident, based on its preliminary assessment and on the information currently known, the company does not currently believe the incident will have a material impact on its business, operations, or financial results.

17:20 EDT AAR Corp. awarded $365M Air Force contract - AAR Government Services has been awarded a $365M firm-fixed-price, indefinite-delivery/indefinite-quantity contract for F-16 Systems Program Office Support at Hill Air Force Base, Utah. This contract provides for F-16 depot work and Service Life Extension Program overhauls. Work is expected to be completed by March 30, 2033. This award is the result of a competitive acquisition. FY21 procurement funds in the amount of $94,873 are being obligated at time of award. Air Force Life Cycle Management Center is the contracting activity.

17:19 EDT Arcus Biosciences to replace Investors Bancorp in S&P 600 at open on 4/7 - Citizens Financial Group (CFG) is acquiring Investors Bancorp (ISBC) in a deal expected to be completed soon pending final closing conditions.

17:03 EDT Arconic names Daniel Fayock chief legal officer - Arconic Corporation has named Daniel Fayock Executive Vice President, Chief Legal Officer and Corporate Secretary. Fayock joins the Arconic Executive Leadership Team and oversees all areas of legal, ethics, compliance and government affairs, as well as provides counsel to the company's leaders and board of directors.

17:01 EDT Micron appoints Fran Dillard as chief diversity inclusion officer - Micron (MU) announced the appointment of Fran Dillard to the role of vice president and chief diversity inclusion officer. Dillard brings more than 20 years of diversity leadership and HR experience to advance the company's diversity initiatives. Dillard was most recently the executive director of global diversity and inclusion enterprise programs, partnerships, and strategic solutions for Lockheed Martin (LMT).

16:59 EDT ITT acquires Habonim for $140M in cash - ITT announced it has acquired privately-held Habonim for $140M in an all-cash transaction. Habonim will become part of ITT's Industrial Process segment. The acquisition closed in the second quarter and is expected to be accretive to ITT's consolidated EBITDA margin. Based in Kfar HaNassi, Israel, Habonim is a designer and manufacturer of valves, valve automation and actuation for the gas distribution, biotech and harsh application service sectors. The company's highly differentiated business model allows for the commercialization of a majority of its products through distribution while maintaining its end-user relationships. Habonim also sells directly to original equipment manufacturers and integrators for customized solutions. The company has operations in Israel, the U.S., and the Netherlands and employs over 200 highly skilled professionals globally.

16:18 EDT Burlington Stores CFO John Crimmins to retire - Burlington announced that John Crimmins will retire from his position as CFO on the earlier of August 31 or the date his successor commences employment. Burlington has initiated an external search for a new CFO and, in order to ensure an orderly transition, Crimmins has agreed to provide consulting services at the request of the company through the end of February 2023.

16:17 EDT Eaton names Heath Monesmith President and Chief Operating Officer - Eaton "announced Heath Monesmith has been named president and chief operating officer of the Electrical Sector, effective July 5, 2022. In this role, he will also have corporate responsibility for the EMEA region and will report to Eaton's Chairman and Chief Executive Officer Craig Arnold. Monesmith most recently served as president and chief operating officer of the Industrial Sector."

16:16 EDT Myomo provides update on progress with China JV - Myomo, Inc. provided an update on the status of its joint venture in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has been paid. The company received $1M of the total $2.7M license fee during March, which will be accounted for as revenue during the three months ended March 31, 2022. David Henry, Myomo's chief financial officer, said, "This license revenue is additive to first quarter product revenue, which on March 9, 2022 we stated would be in the range of $2.6 million to $3.0 million. Our joint venture is making tangible progress toward beginning operations, and we expect the remainder of the license fee will be paid during the second quarter. At that point we will begin transfer of the technology and record the remaining $1.7 million as revenue. In anticipation of this final payment, plans are underway to assist joint venture staff in establishing operations for the production and sale of the MyoPro's for individuals in China with upper-limb paralysis."

16:08 EDT Theravance Biopharma announces results from Study 0170 - Theravance Biopharma announced results from the second Phase 3 study, Study 0170, assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic nOH. Study 0170 was a 22-week Phase 3 study comprised of a 16-week open-label period followed by a 6-week double-blind, placebo-controlled, randomized withdrawal period. The primary endpoint of treatment failure at week 6 of the randomized withdrawal period was defined as a worsening of both Orthostatic Hypotension Symptom Assessment Scale question #1 and Patient Global Impression of Severity scores by 1.0 point. The primary endpoint was not statistically significant for the overall population of patients which included patients with Parkinson's disease, pure autonomic failure and MSA. The odds ratio suggests that patients receiving ampreloxetine had a 40% reduction in the odds of treatment failure compared to placebo. The pre-specified subgroup analysis by disease type suggests the benefit seen in patients receiving ampreloxetine was largely driven by MSA patients. An odds ratio of 0.28 was observed in MSA patients indicating a 72% reduction in the odds of treatment failure with ampreloxetine compared to placebo. The benefit to MSA patients was observed in multiple endpoints including OHSA composite, Orthostatic Hypotension Daily Activities Scale (OHDAS) composite, Orthostatic Hypotension Questionnaire composite and OHSA #1. Notably, patients withdrawn to placebo had a clinically relevant decrease in standing blood pressure; there was no decrease for patients remaining on ampreloxetine. While the same benefit was not apparent in patients with PD or PAF, the Company continues to analyze the data to better understand this observation. Throughout the study, there was no indication of worsening of supine hypertension based on 24-hour monitoring. Data suggest that ampreloxetine was well-tolerated and no new safety signals were identified.

16:07 EDT Castle Biosciences to acquire AltheaDx in up to $140M deal - Castle Biosciences announced it has signed a definitive agreement to acquire AltheaDx. AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that are focused on mental health. IDgenetix is its PGx test for depression, anxiety and other mental health conditions. "As a company, we focus on transforming disease management through the personalized information our innovative tests provide," said Derek Maetzold, Castle's president and chief executive officer. "Similar to our acquisition of Cernostics in December 2021, the pending acquisition of AltheaDx enables us to offer a testing solution that we believe has the potential to accelerate our impact on patient care in an area of high unmet clinical need, significantly expand our in-market expected estimated U.S. TAM to approximately $8 billion and offer incremental value to patients and clinicians over standard of care. Further, this acquisition would enable us to potentially develop a mental health franchise, starting with a test that currently receives Medicare reimbursement for depression." Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65M in initial consideration to AltheaDx security holders, which will consist of $32.5M in cash, subject to adjustments for cash, debt, transaction expenses and working capital, and $32.5M in common stock of Castle. Further, up to an additional $75M in cash and common stock will be payable in connection with the achievement of certain milestones based on 2022, 2023 and 2024 performance and expanded Medicare coverage for IDgenetix. The transaction is expected to close in the second quarter of 2022, subject to customary conditions to closing. Upon closing of the transaction, the executive management team and other AltheaDx staff are expected to stay with Castle. AltheaDx's laboratory and operations are expected to remain in San Diego.

16:05 EDT NewAge gets notification from Nasdaq on delayed 10-K - As previously announced, on March 16 NewAge filed a Notification of Late Filing on Form 12b-25 indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31 would be delayed. In addition, on March 31 , the Company filed a Form 8-K indicating that the Company would be unable to file its Annual Report within the 15-day extension. As expected, on April 1 the Company received a letter from Nasdaq stating that, as a result of the delay, the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250.This notification has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market; however, if the Company fails to timely regain compliance with the Nasdaq Listing Rule, the Company's common stock will be subject to delisting from Nasdaq.Nasdaq indicated that the Company must submit a plan of compliance within 60 days, or no later than May 31, 2022, addressing how it intends to regain compliance with the Nasdaq Listing Rule and, if Nasdaq accepts the Plan, it may grant an extension of up to 180 days from the original filing due date of the Annual Report, or until September 27to regain compliance. The Company is working diligently and expects to file the Annual Report within the 60-day period described above, which would eliminate the need for the Company to submit a formal plan to regain compliance; however, no assurance can be given as to the definitive date on which the Annual Report will be filed.

16:02 EDT SEI names Ryan Hicke as next CEO - SEI announced that Ryan Hicke, Executive Vice President and Chief Information Officer, will become the company's next CEO and a member of its board of directors, effective June 1. Hicke will succeed Founder Alfred West, Jr., who is transitioning to the role of Executive Chairman after successfully leading and growing SEI for more than 50 years. The executive management team, currently reporting to West, will report to Hicke effective June 1. Hicke previously served as a senior vice president, leading SEI's U.K. Asset Management and Private Banking businesses and significantly contributing to the expansion of SEI's global footprint. As chief information officer, he is responsible for SEI's information technology strategy and execution, the company's U.S. investment operations, and leading SEI Sphere, a new business initiative in cyber and data protection services.

14:59 EDT Mailchimp confirms internal tool used to gain access to customer accounts - In an emailed statement, Mailchimp's CISO Siobhan Smyth told The Fly that, "On March 26, our Security team became aware of a malicious actor accessing one of our internal tools used by customer-facing teams for customer support and account administration. The incident was propagated by an external actor who conducted a successful social engineering attack on Mailchimp employees, resulting in employee credentials being compromised. We acted swiftly to address the situation by terminating access for the compromised employee accounts and took steps to prevent additional employees from being affected. We also conducted a robust investigation and engaged outside forensic counsel to understand what happened and the impact. Based on our investigation, we believe that about 300 Mailchimp accounts were viewed and audience data was exported from 102 of those accounts. Our findings show that this was a targeted incident focused on users in industries related to cryptocurrency and finance, all of whom have been notified. We also determined that some accounts' API keys posed a potential vulnerability. Out of an abundance of caution, we disabled those API keys, implemented protections so they can't be re-enabled, and notified affected users. As a result of the security incident, we've received reports of the malicious actor using the information they obtained from user accounts to send phishing campaigns to their contacts. When we become aware of any unauthorized account access, we notify the account owner and immediately take steps to suspend any further access. We also recommend two-factor authentication and other account security measures for our users as added measures to keep accounts and passwords secure. We sincerely apologize to our users for this incident and realize that it brings inconvenience and raises questions for our users and their customers. We take pride in our security culture, infrastructure, and the trust our customers place in us to safeguard their data. We're confident in the security measures and robust processes we have in place to protect our users' data and prevent future incidents."

13:32 EDT Volkswagen reports U.S. Q1 sales down 28.5% to 64,993 units - Volkswagen of America reports Q1 2022 sales of 64,993 units, down 28.5% from Q1 of last year. Reference Link

12:35 EDT AstraZeneca reports ETESIAN Phase IIb trial met primary, secondary endpoints - AstraZeneca (AZN) announced that the ETESIAN Phase IIb trial showed AZD8233, an investigational antisense oligonucleotide, also known as ION449, met the primary endpoint at 50 mg with 73% reduction in low-density lipoprotein cholesterol, or LDL-C, levels, from baseline. The trial also met the secondary endpoints, including significantly reducing proprotein convertase subtilisin/kexin type 9, or PCSK9, levels by 89%, with sustained reductions maintained over the dosing intervals, and through to week 14 at 50 mg dose. AZD8233 was generally well-tolerated during the treatment duration, the company stated. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Today, we are pleased to announce that ETESIAN Phase IIb for AZD8233 demonstrated a clear dose-response for both PCSK9 and LDL-C levels. The results underscore AZD8233's potential best-in-class efficacy profile, and supports its further development as a next generation PCSK9 inhibitor that is easily self-administered monthly." Brett Monia, CEO, Ionis Pharmaceuticals (IONS), said: "The positive results of the ETESIAN study, along with the clinical studies to date, reinforces our confidence that ION449 is a potential new treatment option that may be able to change the current standard of care for patients affected by hypercholesterolemia who have cardiovascular disease." Results from the ETESIAN Phase IIb trial were presented on April 4 at the American College of Cardiology's 71st Annual Scientific Session. Results from the SOLANO Phase IIb trial assessing the safety, efficacy and tolerability of AZD8233 in patients with hypercholesterolemia is anticipated later in 2022, the company stated.

12:00 EDT Gold Fields falls -8.4% - Gold Fields is down -8.4%, or -$1.35 to $14.77.

12:00 EDT Forge Global falls -14.4% - Forge Global is down -14.4%, or -$4.26 to $25.42.

12:00 EDT Twitter rises 25.2% - Twitter is up 25.2%, or $9.89 to $49.20.

11:43 EDT Aziyo Biologics Inc trading resumes

11:08 EDT Canada announces investment of C$259M in General Motors of Canada - The Honourable Francois-Philippe Champagne, Minister of Innovation, Science and Industry, announced an investment of C$259M from the Government of Canada in General Motors of Canada Company. "This investment will secure thousands well-paying, high-quality jobs across GM facilities while advancing the electrification of Canada's automotive sector. Today's investment supports GM's more than $2-billion project to reignite production at its Oshawa Assembly Plant, after operations stopped in 2019, and the transformation of its CAMI Assembly Plant in Ingersoll. This transformation will allow GM's CAMI Assembly Plant to become the first full-scale commercial electric vehicle production facility in Canada. GM's first electric commercial vehicle, the EV600, which uses BrightDrop technology, will be brought into production and commercialized at the CAMI plant in Ingersoll by the end of the year," the government's press release stated. Reference Link

11:03 EDT JX Luxventure signs $30M sales agreement - JX Luxventure announced that, on March 31, 2022, Jin Xuan Luxury Tourism Digital Technology entered into and executed a Framework Agreement on Strategic Cooperation with Ragdoll International Trading. Pursuant to the Agreement, Ragdoll will purchase from JX Hainan cross-border pet foods in the amount of up to $30,000,000 to be distributed on the platforms operated by Ragdoll.

11:02 EDT Air Lease adds 32 Boeing 737 MAX jets to orderbook - Boeing (BA) and Air Lease Corp. (AL) announced the aircraft lessor is expanding its airplane portfolio with an order for 32 additional 737-8 and 737-9 jets. "As the travel market recovers, ALC is increasing its 737 MAX family offering to meet airline demand for modern, fuel-efficient and sustainable operations," the companies stated. "Following our memorandum of understanding with Boeing in February for these 32 737 MAX aircraft, we are pleased to announce the signing of this definitive purchase agreement. We believe that the economic and operating advantages of the 737 MAX will serve our airline customers well as they favor modern, fuel efficient aircraft," added John Plueger, CEO and President of Air Lease Corporation.

10:24 EDT Borr Drilling announces new contracts, extensions for jack-up drilling rigs - Borr Drilling Limited is pleased to announce it has been awarded new contracts and extensions for 5 of its premium jack-up drilling rigs. These awards increase the company's backlog by approximately 2,530 days, excluding optional periods. The premium jack-up drilling rig "Gunnlod" has secured a contract with an undisclosed operator in Southeast Asia. This contract is expected to commence in direct continuation of its current contract. The work will cover 11 wells with an anticipated duration of 186 days plus options. The premium jack-up drilling rig "Mist" had options exercised by PTTEP for a total duration of approximately 3.5 months and it is now expected to remain contracted with the customer until Q4 2022. The premium jack-up drilling rig "Saga" has secured a contract with an undisclosed operator in Southeast Asia. This contract will commence in direct continuation of its current contract and the work will cover a 1-well program with an anticipated duration of 45 days. Additionally, the Company has secured long-term contracts in the Middle East with an undisclosed operator for 2 of its premium jack-up drilling rigs. The contracts have a firm duration of 3 years plus options each and are expected to commence in the second half of 2022. These awards increase the company's contracted fleet to 20 rigs out of a total of 23 delivered rigs. Borr Drilling remains in constructive discussions with its lenders in relation to the deferral or refinancing of its debt maturing in 2023 and expects such discussions to be successfully concluded on or before June 30th, 2022.

10:01 EDT BetMGM launches online sports betting and iGaming platforms in Ontario, Canada - BetMGM announced the launch of its online sports betting and iGaming platforms in Ontario, Canada. Ontario is BetMGM's first international market and the 23rd overall in which a BetMGM product is available. BetMGM has also established partnerships with legendary Canadian athletes to help reach players across the country. Hockey Hall of Fame member Wayne Gretzky and Edmonton Oilers captain Connor McDavid will appear in BetMGM's upcoming marketing campaigns, in addition to the brand's advertisements featuring Academy Award-winning actor Jamie Foxx and Basketball Hall of Fame member Kevin Garnett.

10:00 EDT Scor ADR falls -6.1% - Scor ADR is down -6.1%, or -34c to $5.32.

10:00 EDT Jumia Technologies rises 18.5% - Jumia Technologies is up 18.5%, or $1.75 to $11.23.

10:00 EDT Twitter rises 22.9% - Twitter is up 22.9%, or $9.02 to $48.33.

09:47 EDT Arcos Dorados falls -3.7% - Arcos Dorados is down -3.7%, or -30c to $7.85.

09:47 EDT Forge Global falls -6.9% - Forge Global is down -6.9%, or -$2.06 to $27.62.

09:47 EDT Starry rises 17.1% - Starry is up 17.1%, or $1.36 to $9.31.

09:42 EDT JPMorgan says 'most top holders' support letting Dimon be non-executive Chair - In a regulatory filing, JPMorgan stated: "As part of the annual review of its leadership structure, this year, the Board again considered how shareholders may best be served upon the next management transition. The Board recognizes the support received by a shareholder proposal at the Firm's 2021 Annual Meeting requesting separation of the Chair and CEO roles at the next change in leadership. Following that meeting, the Board asked the Firm to broaden its usual scope of shareholder outreach, with a heightened focus on obtaining feedback on the potential separation of the Chair and CEO roles in the context of CEO succession planning. Ultimately, the Firm received feedback from shareholders across more than 50 engagements, representing approximately half of the Firm's outstanding common stock, and presented the results of the engagements to the Board. While our shareholders recognized the importance of the Board's ability to determine its leadership structure in the context of the current structure, many expressed a general preference for separate Chair and CEO positions. Notably, a substantial majority of those with whom we engaged, including most of our top holders, indicated support for a policy that would enable our current CEO to serve as non-executive Chair at the next leadership transition."

09:35 EDT NVX Stock trading resumes

09:31 EDT Lead Edge Growth Opportunities Ltd trading halted, volatility trading pause

09:30 EDT NVX Stock trading halted, volatility trading pause

09:27 EDT Advanced Human Imaging concludes formal agreements with BizBaz - Advanced Human Imaging is pleased to update shareholders of the completion of the Master Services Agreement with Singapore based digital health and financial intelligence platform BIZBAZ. The parties have executed the standard AHI MSA which entails the legal and contractual terms in which AHI agrees to grant BizBaz the right to use AHI's licensed Software Development Kits for IOS and Android platforms for body circumference measurements, face scan measurements and related intellectual property once integrated into the BizBaz application/platform. The MSA incorporates the following information and guidelines: commercial undertakings, software development kit, end user license, technology support, data processing agreement, fee schedule and professional services, including implementation support and training services, which are to be provided by AHI within the agreement with BizBaz. The initial term of the MSA is for one year from commencement and will automatically extend for subsequent consecutive periods each of equivalent length to the initial term. Early termination procedures are included for either party to the MSA. The financial impact of this MSA on AHI cannot be currently quantified and there are no minimum order requirements contained in the agreement.

09:22 EDT Nutanix names Mandy Dhaliwal as Chief Marketing Officer - Nutanix announced that it has named Mandy Dhaliwal as Chief Marketing Officer and Shyam Desirazu as Head of Engineering. Each brings more than two decades of experience building and scaling high performing, mission-driven organizations. They will both report to Rajiv Ramaswami, the Chief Executive Officer at Nutanix.

09:22 EDT Moderna launches Moderna Charitable Foundation - Moderna announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations. The Moderna Foundation was established by the Moderna Board of Directors, which approved an initial up-front endowment of $50 million. The Foundation and its grant program will focus on charitable programs with a particular emphasis on supporting local and global communities impacted by the pandemic, advancing scientific education and innovation, promoting public health and access to healthcare, and advocating for inclusion and diversity. Today, the Moderna Foundation announced approximately $5 million in initial grants to five local and global nonprofit organizations working to address these areas of need.

09:20 EDT Qualcomm completes acquisition of Arriver from SSW Partners - Qualcomm announced it has completed its acquisition of Arriver from SSW Partners, enhancing Qualcomm Technologies ability to deliver open, fully integrated, and competitive Advanced Driver Assistance System solutions to automakers and Tier-1 suppliers at scale. As a result of the acquisition, Qualcomm Technologies will incorporate Arriver's Computer Vision, Drive Policy and Driver Assistance assets into its leading Snapdragon Ride Platform portfolio, building on its previous collaboration with Arriver, when owned by Veoneer.

09:18 EDT Matterport to showcase digital twins at Space Jam event - Matterport announced it will host the next installment of the Matterport Space Jam virtual event series, featuring five of its app developers that are building software solutions on the Matterport platform for retailers. The event will take place on April 28 at 8:30 am PT, offering attendees an opportunity to learn how five Matterport app developers and partners build solutions that enhance the value of Matterport digital twins for retail businesses. During the event, each Matterport app developer will demonstrate its products in respective 5-minute sessions and field questions from attendees. After demonstrations and questions have concluded, attendees can vote on their favorite presentation. The event will feature the following Matterport app developers: GUS - a tool, called Portfolio, that enables retailers to create 3D virtual showrooms and seamlessly integrate e-commerce solutions that are fast and efficient. Living3D - an integrated solution that helps retailers bolster their lead generation, promote their products, and virtually connect to customers. Retail VR - a dynamic platform that creates merchandising simulations and virtual product staging for the retail community. Treedis - a market leader in creating 3D and metaverse experiences, Treedis turns brick-and-mortar retail stores into immersive, virtual experiences with its innovative V-commerce solution. VR Experience by L2IOT - Integrated with a customizable service robot, L21OT is a powerful wayfinding solution to create interactive tours and customer engagement for retailers and large space owners.

09:16 EDT Rogers Communications to deploy two more cellular towers along Highway 16 - Rogers Communications announced the company will deploy two more cellular towers as it continues ahead with construction of its wireless service expansion project along Highway 16. Rogers crews started construction on the first of 12 new towers last year that will service the area of highway between Prince Rupert and Prince George known as the Highway of Tears. When completed, the additional two towers will provide 26 km of new wireless coverage along Highway 16 southwest of Hazelton.

09:14 EDT Scilex announces March preliminary March ZTlido gross sales of $8.1M - Scilex Holding Company , a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, (SRNE), announced an increase of 53% year-over-year preliminary unaudited gross ZTlido sales in March. ZTlido sold $8.1 million in March 2022 compared to $5.3 million in March 2021. In 1Q2022, the preliminary unaudited gross sales for ZTlido are approximately $18.4 million, compared to $14.6 million in 1Q2021, representing a growth of 26%. The Scilex commercial team has demonstrated success in expanding access and currently has prioritized and targeted select payor accounts representing approximately 200 million of over 300 million covered lives in the US. Scilex Holding Company and Vickers Vantage Corp. I (VCKA), a special purpose acquisition company sponsored by Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI Pte Ltd, entered into a definitive business combination agreement on March 17, 2022. Upon the closing of the transaction, the combined company will be renamed Scilex Holding Company, and its common stock is expected to be listed on Nasdaq under the ticker symbol "SCLX". The boards of directors of each of VCKA, Scilex and Sorrento have unanimously approved the proposed transaction. The closing of the transaction, which is expected to occur by the third quarter of 2022, is subject to the approval of VCKA's shareholders and the satisfaction or waiver of certain other customary closing conditions.

09:11 EDT WWE reports WrestleMania 38 became highest-grossing, most-attended event - WWE announced that WrestleMania 38 became WWE's highest-grossing and most-attended event in company history. It saw 156,352 fans from all 50 states and 53 countries converge on AT&T Stadium in Dallas over the course of two nights, surpassing the previous gate and attendance records set by WrestleMania 32 in 2016.

09:10 EDT Nordstrom reports retirement of chief marketing officer Scott Meden - Nordstrom announced the retirements of Scott Meden, chief marketing officer, and Geevy S.K. Thomas, president of Nordstrom Rack. Nordstrom, Inc. also announced the appointments of Ken Worzel and Jamie Nordstrom to the newly created roles of chief customer officer and chief stores officer, respectively.

09:09 EDT Intevac receives $54M order for multiple 200 Lean systems - Intevac announced the receipt of a $54M order for multiple 200 Lean systems. The order includes eight expanded-module systems, each of which are configured with 28 process chambers for the production of advanced hard disk drive, or HDD, media. Scheduled to ship over multiple quarters beginning in mid-2023, this order will be reflected in the company's backlog at its fiscal first-quarter end of April 2. This order also includes a down payment provision, due in the third fiscal quarter of 2022, which will help fund inventory purchases in support of this significant system build-out.

09:07 EDT AvidXchange further invests in HOA industry with appointment of Pizzico as VP - AvidXchange announced its increased focus in the Homeowners Association, HOA, industry with the hiring of Michael Pizzico as Vice President, VP, of the business line. In this role, Michael will be responsible for sales performance as well as leading all strategies, growth and revenue opportunities, and supporting actions including partnerships. "At AvidXchange, we understand that the middle market is unique in that deep domain expertise is highly valued," said Michael Praeger, CEO and Co-Founder of AvidXchange. "Our customers appreciate that we know the industry, and the issues they are facing, which is why investments like this are the right next steps for us in HOA with Michael Pizzico."

09:06 EDT Roku and Amazon reach multi-year extension on distribution pact, no terms - Roku (ROKU) issued the following statement confirming that it has reached a multi-year extension of its distribution agreement with Amazon (AMZN): "Roku and Amazon have reached a multi-year extension for their distribution agreement. Customers can continue to access the Prime Video and IMDb TV apps on their Roku devices." Terms of the agreement were not disclosed.

09:05 EDT Lockheed Martin, Intel sign MOU to advance 5G-ready communications - Lockheed Martin (LMT) and Intel (INTC) are leveraging their expertise in technology and communications to bring together innovative 5G-capable solutions, enabling faster and more decisive actions for 21st century security. A memorandum of understanding signed late last year expands the ongoing strategic relationship between the two companies to align 5G-enabled hardware and software solutions for the Department of Defense.

09:04 EDT Pacific Biosciences enters agricultural collaboration with Corteva Agriscience - PacBio (PACB) announced a new collaboration with global agriculture company, Corteva Agriscience (CTVA), to develop custom, end-to-end workflows for plant, pest and microbial sequencing. The project focuses on establishing high-throughput workflows in DNA extraction and library preparation in alignment with the tens of thousands of samples sequenced annually as part of Corteva's seed and crop protection research and production pipelines. "This collaboration will allow us to help Corteva Agriscience characterize complex plant and microbial genomes more efficiently," said Christian Henry, President and Chief Executive Officer of PacBio. "We are proud to provide a sequencing platform to Corteva Agriscience for use in its development of products that help farmers modernize agriculture while driving productivity gains for farmers and resiliency to help solve the problem of feeding the world." The initial phase of the collaboration, aimed for completion in the third quarter of 2022, will be developing the scaled DNA extraction and library preparation workflows to take advantage of the extensive collection of Corteva crop, pest and microbial samples. Upon success in the development of these workflows, the collaboration will look to expand sequencing capabilities alongside the sample preparation workflows.

09:02 EDT Penn National announces launch of theScore Bet in Ontario - Penn National announced that its subsidiary, theScore Bet, has officially launched theScore Bet mobile Sportsbook and Casino in Ontario. TheScore Bet, which is available on iOS and Android devices, went live at 12:01 AM, ET on April 4.

09:02 EDT QCR Holdings appoints Griesemer to board of directors - QCR announced the appointment of John Griesemer to the QCRH Board of Directors, Guaranty Bank's parent company. Griesemer has served as President, Chief Executive Officer of Erlen Group since 2018, and a member of the Erlen Group Board of Directors since 1993.

08:59 EDT Dolby announces general availability of Dolby.io Transcode API - Dolby Laboratories announced that the Dolby.io Transcode API is moving from beta to general availability. The Dolby.io Transcode API is an API-driven media conversion tool for easily creating high-quality, file-based media workflows, and is designed to help businesses and developers of any level of media experience quickly add video into their apps and services. The Transcode API provides conversion tools for streaming and delivering content over the web, making it easy to get started creating high-quality media for any screen. From developers who need to handle large volumes of user-generated content to businesses with recorded video intended for massive audiences, nearly anyone who processes media can benefit from the Transcode API.

08:51 EDT WISeKey says NFT tech helping brands mint luxury watches - WISeKey International Holding announced that it is supporting luxury brands' efforts to NFT their watched as unique, digital assets, unalterably registered on a blockchain, that can be bought and sold like any other product or commodity. The technology also allows brands to acquire NFTs of digital representations of watches without the need to acquire the physical one as millennial consumer freely admit that they prefer a metaverse watch versus a physical mechanical watch. Strong demand for luxury metaverse is expected to grow. Morgan Stanley is predicting a virtual luxury goods market would be worth $50 billion by 2030.

08:46 EDT Sigma Labs appoints Jacob Brunsberg as CEO - Sigma Labs announced Jacob Brunsberg, President and COO, has been appointed as CEO of Sigma Labs, effective April 1st. Mark Ruport, Sigma labs' CEO will transition to the role of Chairman of the Board of Directors, replacing John Rice who will continue to serve as a Director. Brunsberg joined Sigma Labs in September 2021 as Senior Vice President and subsequently was promoted to President and COO with responsibility for product direction, strategic relationships, sales, marketing and engineering.

08:44 EDT Glimpse Group appoints James Watson as CMO - The Glimpse Group announced the appointment of James Watson as its Chief Marketing Officer. Prior to joining Glimpse, James was the founder of XRTech Marketing, a strategic marketing consulting firm focused on helping XR companies align their products with market needs.

08:43 EDT CCL Industries to acquire Adelbras Brazil, terms not disclosed - CCL Industries announced it has signed a binding agreement to acquire privately owned Adelbras Industria e Comercio de Adesivos Ltda. and Amazon Tape Industria e Comercio de Fitas Adesivas, headquartered in Vinhedo near Sao Paolo with an additional operation in Manaus in the Amazon tax free zone. Adelbras is Brazil's second largest producer of adhesive tapes with the majority of sales derived from masking, bonding & packaging applications broadly sold through retailers & distributors to consumers & small businesses under the Adelbras brand name. A smaller proportion is sold for industrial use directly to larger customers, mainly in the durable goods space. Fiscal 2021 sales were $105.2 million with adjusted EBITDA estimated at $18.7 million. The debt free, all cash purchase consideration, subject to customary closing conditions, is approximately $155.4 million; closing is planned for the second quarter of 2022. The new business will largely be reported as part of Avery, with the smaller industrial portion added to CCL Design.

08:42 EDT Lucid Diagnostics, PAVmed says updated ACG guideline supports BE screening - Lucid Diagnostics (LUCD) and majority-owned subsidiary of PAVmed (PAVM) announced that a newly updated American College of Gastroenterology ACG, clinical guideline supports esophageal precancer Barrett's Esophagus", "BE screening to prevent highly lethal esophageal cancer EAC utilizing its EsoGuard DNA Test on samples collected with its EsoCheck Cell Collection Device. It also provided an update on, and planned response to, a proposed Local Coverage Determination on molecular testing for esophageal precancer and cancer published by Medicare Administrative Contractor Palmetto GBA's MolDX Program, triggering a comment period in advance of a public meeting...The clinical guideline first reiterates the ACG's long-standing recommendation for esophageal precancer screening in at-risk patients with gastroesophageal reflux disease GERD , commonly known as chronic heartburn, acid reflux, or simply reflux..."Publication of this updated ACG clinical guideline is a critical milestone which has the potential to save many lives by, for the first time, driving widespread screening to prevent esophageal cancer deaths through the early detection of esophageal precancer," said Lishan Aklog M.D., Lucid's Chairman and Chief Executive Officer. "Although, for over a decade, gastroenterology clinical guidelines have recommended esophageal precancer screening in GERD patients with long-established risk factors, very few patients undergo endoscopic screening-making the many thousands of annual esophageal deaths in the U.S. a profound and preventable tragedy. EsoGuard and EsoCheck represent the only 'swallowable, nonendoscopic capsule device combined with a biomarker' currently available in the U.S. to serve as such a widespread screening tool to prevent these tragic deaths." The proposed LCD, which the CMS website explicitly characterizes as a "work in progress" for "public review," outlines criteria that MolDX expects upper gastrointestinal precancer and cancer molecular diagnostic tests to meet. These criteria include active GERD with at least two risk factors, as well as evidence of analytic validity, clinical validity, and clinical utility. ...The publication of the proposed LCD triggers a written comment period which extends until May 14. MolDX will also hold an open meeting on May 10 during which stakeholders and other interested parties will have the opportunity to address the proposed LCD. A final LCD will not be issued until the MAC has had the opportunity to assess and consider these comments.

08:40 EDT Centerra Gold enters agreement with Kyrgyzaltyn, Government of Kyrgyz Republic - Centerra Gold announced that it has entered into a global arrangement agreement with Kyrgyzaltyn JSC and the Government of the Kyrgyz Republic to effect a clean separation of the parties, including through the disposition of Centerra's ownership of the Kumtor Mine and investment in the Kyrgyz Republic, the elimination of Kyrgyzaltyn's involvement and interest in the Company, and the resolution of their disputes. Centerra understands that the Agreement has been approved by the Government of the Kyrgyz Republic, including both the Kyrgyz Parliament and the Cabinet of Ministers. The Agreement provides for, among other things, Kyrgyzaltyn transferring to Centerra all of its 77.4 million Centerra common shares for cancellation, representing an approximate 26% equity interest in the Company, for an aggregate purchase price of approximately C$972 million. In satisfaction of the purchase price, Kyrgyzaltyn will receive from Centerra a 100% equity interest in the Company's two Kyrgyz subsidiaries and, indirectly, the Kumtor Mine, plus a cash payment of approximately US$36 million. In connection with the Share Exchange, the Agreement also is conditioned on the full and final release of all claims of the parties, termination of all legal proceedings involving the parties in all jurisdictions with no admissions of liability and payment by Centerra of US$50 million to KGC at closing of the Arrangement on account of an inter-company balance. Subject to the satisfaction or waiver of the conditions precedent to the Arrangement described below, the parties expect the Arrangement to close no later than 90 days following the signing of the Agreement. The Arrangement comprises the following principal elements: Centerra receiving all of its common shares held by Kyrgyzaltyn, representing an approximately 26% equity interest in Centerra, for an aggregate purchase price of approximately C$972 million. Upon receipt, Centerra will cancel the shares surrendered. Kyrgyzaltyn receiving a 100% stake in the Company's two Kyrgyz subsidiaries, Kumtor Gold Company CJSC and Kumtor Operating Company CJSC, and a cash payment of approximately US$36 million, in satisfaction of the purchase price for Kyrgyzaltyn's Centerra common shares. Approximately US$25 million of the cash payment will be withheld by Centerra and remitted to the Canadian tax authorities on account of Canadian withholding tax payable by Kyrgyzaltyn on the Share Exchange and the balance of the cash payment of approximately US$11 million will be paid to Kyrgyzaltyn on closing of the Arrangement. The Kyrgyz Republic and Kyrgyzaltyn assuming all responsibility for the Kumtor Mine, including all reclamation obligations. Full and final releases of all claims of the parties. All environmental, tax and other claims, fines, penalties or proceedings, including all criminal investigations and proceedings, in the Kyrgyz Republic to be withdrawn and terminated to Centerra's sole satisfaction within 45 days of the date of the Agreement. Binding international arbitration proceedings previously commenced by the Company against the Government of the Kyrgyz Republic and Kyrgyzaltyn are to be suspended within two business days following the date of the Agreement and terminated within two business days of the closing of the Arrangement. No further steps are to be taken by the Kyrgyz Republic or Centerra in relation to the proceedings commenced by the Company in the Ontario Superior Court of Justice against Tengiz Bolturuk, a former member of Centerra's Board of Directors, from the date hereof. From the closing of the Arrangement, Centerra will consent to an order setting aside the judgement issued in the Ontario Superior Court of Justice against Mr. Bolturuk on February 15, 2022. Subject to certain conditions and following the withdrawal and termination of the Kyrgyz Proceedings, KGC and KOC will work together with the Kyrgyz Republic to petition the court to dismiss the Chapter 11 proceedings in U.S. Bankruptcy Court for the Southern District of New York, effective as of the closing of the Arrangement. Centerra extinguishing the inter-company balance between Centerra and KGC by paying US$50 million to KGC on closing of the Arrangement and, as to the balance, through an offsetting dividend to be declared by KGC immediately prior to closing of the Arrangement. The resignation from Centerra's Board of Directors of Kyrgyzaltyn's two nominees and the termination of the shareholders agreement between, among others, Centerra and Kyrgyzaltyn. Termination of all agreements entered into by Centerra in respect of the Kumtor Project vis-a-vis Centerra's rights and obligations. Transfer of the Kumtor reclamation trust funds to a Kyrgyz reclamation account held by KGC. There can be no assurance that Kyrgyzaltyn and the Kyrgyz Government will not take unilateral actions which are inconsistent with their obligations under the Agreement or that the conditions precedent to the Arrangement will be satisfied in a timely manner or at all. There can similarly be no assurance that the Arrangement will be approved by Centerra shareholders or the Ontario court, as described below, or that the Arrangement will not be challenged by third parties. If Centerra is unable to complete the Arrangement in a manner that provides for a clean separation from Kyrgyzaltyn and the Kyrgyz Republic, including the termination or withdrawal of Kyrgyz Proceedings to its satisfaction, the Arrangement may not close. Accordingly, there can be no assurance that the Arrangement will be consummated on the terms described herein or at all.

08:38 EDT ADDvantage announces leadership changes in telecommunications segment - ADDvantage Technologies announced leadership changes at its Triton Datacom and Nave Communications business units. The changes include: Damon Slachter was promoted to President of Triton Datacom. Slachter started his career at Triton Datacom in 2013. Mike Burch was promoted to President of Nave Communications. Burch began his career with Nave in 2004. Reginald Jaramillo Leal, who previously served as President of Telecommunications, overseeing both Triton and Nave, has left the company to pursue other opportunities. Both Slachter and Burch will report to Michael Rutledge, Chief Financial Officer of ADDvantage Technologies.

08:36 EDT eFfector CMO Patel resigns to pursue new opportunity - eFFECTOR Therapeutics announced that its chief medical officer, CMO, Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer. In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022.

08:34 EDT Bragg Gaming to launch iGaming content in Ontario - Bragg Gaming announced that it has secured content distribution agreements with multiple iGaming operators pursuant to the supplier license it received from the Alcohol and Gaming Commission of Ontario, or AGCO, with several more deals in the pipeline. The agreements contemplate a broad range of its proprietary, exclusive iGaming content and will be announced as Bragg's customers, including several well-known iGaming brands, go live in the newly regulated Ontario iGaming market.

08:32 EDT Vimeo appoints Munson as Chief Financial Officer - Vimeo announced the appointment of Gillian Munson as Chief Financial Officer, effective immediately. Gillian brings 30 years of finance and operational experience in the technology industry. Gillian will report to Vimeo Chief Executive Officer Anjali Sud and oversee all corporate finance, accounting, investor relations and administrative functions. Gillian most recently served as CFO at Iora Health, where she oversaw the company's financial management and strategy. Vimeo's outgoing CFO Narayan Menon will remain available to the company as an Executive Advisor through the end of 2022.

08:31 EDT Ardmore Shipping announces sale and time-charter back of vessels - Ardmore Shipping announced that it has agreed terms for the sale of three 2008-built MR product tankers to Leonhardt & Blumberg for an aggregate price of $40M. Following completion of the sales and the prepayment of financing associated with the vessels, the transaction will generate net cash of approximately $15M to Ardmore, which will be used for general corporate purposes. Immediately following the completion of the sales, which are expected to take place in the second quarter, Ardmore will time charter each vessel from Leonhardt & Blumberg for a minimum of two years. Completion of each of the vessel sales is subject to the satisfaction of certain conditions, including, for one vessel, a proposed closing date currently in advance of the current purchase lease option exercise date for that vessel.

08:29 EDT PHI Group signs agreement with Ngoc Thien Phu Rice Export Import JSC - PHI Group announces that Vietnam-based Ngoc Thien Phu Rice Export Import JSC has signed an agreement with PHI Group to participate in PHILUX Global Food Fund, PGFF. According to the agreement, NTP will contribute a mutually agreed amount of capital for the setup and initial operating budget of the PGFF and hold 49% ownership of the general partners' portion of this fund. PGFF will focus on food and food-related agricultural investment opportunities in Vietnam and other countries as well. NTP has engaged Swiss-based Buhler Group to build the first-ever state-of-the-art European-standard factory in Vietnam, also the biggest one in the Southeast Asia region, for processing various high quality clean rice products which are highly sought after in many countries. NTP has registered with the US FDA for exporting its products to the US market, and the company has also secured other certifications to make its agricultural products available in the European and Middle East markets. Henry Fahman, Chairman and CEO of PHI Group, Inc. stated: "We are delighted to collaborate with NTP in this program and believe by capitalizing on our combined experience and networks we are well positioned to serve the needs of agricultural development in Vietnam and other nations as well as create significant enduring benefits for both companies, for our shareholders and all other stakeholders. In addition, we will assist NTP to list its stock on the U.S. Nasdaq Stock Markets in the near future."

08:27 EDT Lexicon welcomes new guidelines for management of heart failure - Lexicon Pharmaceuticals welcomes new guidelines for the management of heart failure issued jointly this past weekend by the American Heart Association, AHA, the American College of Cardiology, ACC, and the Heart Failure Society of America, HFSA. The guidelines now recommend the use of SGLT2 inhibitors in the prevention and treatment of heart failure with the highest-level recommendations among classes of therapy in each category. The guidelines recommend SGLT2 inhibitors for the treatment of heart failure with reduced ejection fraction with a recommendation equivalent to preexisting standard-of-care classes of therapy and for the treatment of heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction with a recommendation stronger than for any other class of therapy. In support, the guidelines specifically cite clinical trials of two selective SGLT2 inhibitors recently approved for heart failure and the SOLOIST-WHF study of dual SGLT1 and SGLT2 inhibitor sotagliflozin in patients admitted for worsening heart failure. The guidelines also highlight the need to improve optimization of medical therapies during heart failure hospitalizations.

08:26 EDT Array to supply advanced tracker technology for solar storage project in US - Array Technologies announced it has entered into an agreement to supply nearly 1GW of DuraTrack HZ v3 single-axis solar trackers for the Gemini solar project. The project will store over 1.4 GWh of solar power and is estimated to be worth more than $1B. Kiewit Power Constructors is serving as the engineering, procurement and construction firm on the project. "As solar energy accounts for an increasing portion of the world's electricity supply, energy storage will play a crucial role in optimizing renewables and ensuring power is available during periods of peak demand," said Travis Rose, Chief Revenue Officer at Array Technologies. "Project Gemini is historic for its size and scale, and we are well-positioned to optimize it for maximum energy generation while limiting installation time, LCOE and maintenance requirements." Array's trackers are scheduled to begin deliveries in Q2 of 2022 with project completion planned for the end of 2023. The project site will be located on Bureau of Land Management land in Overton, NV, 30 miles Northeast of Las Vegas, and will supply power to Nevada Energy, a public utility which generates, transmits, and distributes electric service in northern and southern Nevada.

08:23 EDT BioRestorative Therapies announces cGMP manufacturing facility certification - BioRestorative Therapies announced that it has completed testing and certification of its clinical grade cell therapy manufacturing facility. The cGMP manufacturing facility is a three suite ISO 7 certified clean room environment. The facility will support BioRestorative's clinical manufacturing needs for its active Phase 2 clinical trial targeting chronic lumbar disc disease. "Possessing the capability to produce clinical grade therapeutics in-house provides us with valuable quality control and oversight in connection with our Phase 2 clinical trial manufacturing process. The importance of ensuring that BRTX-100 is produced under the defined standards of quality and release criteria cannot be overly emphasized", said Lance Alstodt, the Company's CEO. In addition to supporting the manufacturing needs for the BRTX-100 Phase 2 trial, BioRestorative's facility will also provide clinical production of the Company's pipeline of clinical and investigational cell therapy candidates.

08:22 EDT CymaBay announces publication of results from a Phase 2 study of seladelpar - CymaBay Therapeutics announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis, PBC, have been published in the Journal of Hepatology. This 52-week, phase 2, dose-ranging, open-label study examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with PBC who were receiving or intolerant to first-line therapy with ursodeoxycholic acid. Eligible patients were enrolled with a minimum serum alkaline phosphatase levels of 1.67 times the upper-limit-of-normal, U/L, and which were on average in excess of 318 U/L. Seladelpar was administered orally once daily at 2 mg, 5 mg or 10 mg for 12 weeks, after which doses could be increased up to 10 mg if needed to improve treatment response. Cirrhosis was present in 21% of patients; 71% had pruritus. An interim primary efficacy analysis of ALP change from baseline at Week 8 found that seladelpar treatment provided 26%, 33%, and 41% reductions for the 2 mg, 5 mg and 10 mg doses, respectively. Responses were maintained or improved at Week 52 which included dose escalation in 91% and 80% of the 2 mg and 5 mg cohorts, respectively. At Week 52, the composite biochemical response rates were 64%, 53%, and 67%, and ALP normalization rates were 9%, 13%, and 33% in the 2 mg, 5 mg, and 10 mg cohorts, respectively. The pruritus visual analog scale score was also decreased in the 5 mg and 10 mg cohorts. There were no treatment-related serious adverse events, AEs, and 4 patients discontinued due to AEs. A companion manuscript of results from this study were also published in the journal Liver International. It reported the effects of seladelpar treatment on patient reported symptoms of pruritus, sleep and fatigue through one year of treatment. CymaBay is currently enrolling RESPONSE, a global phase 3 study of seladelpar in patients with PBC that is intended to confirm these results. Seladelpar's development program also includes ASSURE, a global phase 3 long-term study that is expected to contribute safety and efficacy data on more than 300 patients treated with seladelpar.

08:21 EDT KBS Builders wins $9M contract to manufacture four dormitories - Star Equity Holdings announced that its KBS Builders business has signed an approximately $9M contract to manufacture 72 modules for the construction of 4 new dormitories for a college in New England. This project is the largest contract in KBS's history and launches KBS's expansion into the student housing segment. Production is expected to commence in the second quarter of 2022.

08:19 EDT Enphase Energy expands manufacturing capacity with Flex in Romania - Enphase Energy announced today that it has expanded its nearly 15-year relationship with global diversified manufacturer Flex. Starting in the first quarter of 2023, Flex's factory in Timisoara, Romania will begin manufacturing Enphase microinverters for the European market, addressing the region's rapid growth and demand for residential solar due to rising energy prices and the increased adoption of electric vehicles, EV, and heat pump technology. The new manufacturing site in Romania enables Enphase Energy to increase global capacity and improve delivery times to its customers in Europe. More clean energy technology like solar and batteries across the continent will provide greater energy security for consumers as the dependence on fossil fuels continues to decline. "This is a transformational moment for clean energy in Europe and across the globe," said Badri Kothandaraman, president and CEO of Enphase Energy. "Policymakers are setting ambitious new targets to help accelerate the transition to a more electrified future, and we expect to help meet the growing demand with our leading solar, battery, and EV charging solutions. I want to thank Flex for being such a strong partner in our global manufacturing strategy and supporting our efforts to better serve our customers while maintaining our product quality."

08:18 EDT OrthoPediatrics announces acquisition of MD Orthopaedics - OrthoPediatrics announced the acquisition of MD Orthopaedics, including its bracing product lines and the patented Mitchell Ponseti Ankle-Foot Orthosis, AFO, system for the treatment of clubfoot. OrthoPediatrics will acquire MD Orthopaedics in a transaction valued up to $19.6M. Under the terms of the agreement, OrthoPediatrics will acquire MD Orthopaedics for an upfront cash payment of $8.2M and $8.9M in company stock, with an additional $2.5M in restricted stock which vest after three years. MD Orthopaedics is a privately held orthopedic device company that has developed and commercialized a custom fit bracing system that has supported the dissemination of the Ponseti Technique - the gold standard treatment for clubfoot. David Bailey, Chief Executive Officer of OrthoPediatrics, commented, "We believe MD Orthopaedics will be a springboard for our expansion into pediatric orthopedic non-surgical treatments for kids and further supports our mission of helping children living with orthopedic conditions. The addition of non-operative specialty bracing systems advances our growth strategy of providing a broad product portfolio uniquely designed to treat children while surrounding pediatric orthopedic surgeons with the most comprehensive product offering in the market."

08:17 EDT Verisk Analytics assembles Climate Advisory Council - Verisk has formed the Verisk Climate Advisory Council. Council members will provide strategic guidance and feedback on climate change solutions Verisk is developing, such as the climate conditioning of the company's extreme event models, and present research, specific to each members' specialty area, regarding the evolving state of climate change. The ongoing research by the experts on this council will help ensure that Verisk is well-informed on the latest climate change research and analyses to help drive its development of industry-leading products and services. The Verisk Climate Advisory Council is currently comprised of the following climate experts: Dr. Cindy Bruyere is the Director for the Capacity Center for Climate and Weather Extremes at the National Center for Atmospheric Research. Dr. Henk Dijkstra is a professor of dynamical oceanography at the Institute for Marine and Atmospheric research Utrecht and the Director of the Centre for Complex Systems Studies at Utrecht University. Dr. Kenneth E. Kunkel is a research professor of atmospheric sciences at North Carolina State University and lead scientist for assessments with the North Carolina Institute for Climate Studies. Dr. Park Williams is an associate professor in the Department of Geography at the University of California, Los Angeles.

08:15 EDT DraftKings, Mashantucket Pequot Tribal Nation expand relationship - DraftKings and the Mashantucket Pequot Tribal Nation announced they have agreed to a deal to expand their relationship and pave the way to offering the DraftKings online and retail sports betting experience in Puerto Rico, subject to applicable licenses and regulatory approvals being obtained. The announcement comes following Foxwoods and DraftKings having successfully launched sports betting and iGaming in Connecticut on October 19, 2021. The DraftKings retail sportsbook will be located inside the Foxwoods El San Juan Casino and is expected to open in the coming weeks, pending receipt of applicable licenses and regulatory approvals. Once complete, the space will feature a massive video wall, bar and dining services, two over the counter ticket windows and six betting kiosks. In January 2021, the Mashantucket Pequot Tribal Nation and Foxwoods announced plans to reopen the iconic El San Juan Casino as the "Foxwoods El San Juan Casino". The redevelopment of the luxurious casino destination included $137.5 million in resort enhancements, including the reopening of the renowned Tropicoro entertainment venue. In addition to online and retail sports betting, DraftKings will have the opportunity, pending receipt of applicable licenses and regulatory approvals, to provide customers in Puerto Rico with its legacy daily fantasy sports product, which is currently available in 44 states in the United States and operational in six countries internationally.

08:13 EDT Aligos Therapeutics selects ALG-097558 to advance inro development - Aligos Therapeutics announced that it has selected ALG-097558, a broad spectrum coronavirus protease inhibitor, as its drug candidate to move forward into development. The program is part of the collaboration and license agreement with KU Leuven, including its Centre for Drug Design and Discovery, CD3, a drug discovery unit and investment fund of KU Leuven, and the Rega Institute for Medical Research. "Despite the progress that vaccines have brought to combating the global COVID-19 pandemic, there remains an ongoing need for an orally administered potent antiviral therapeutic that broadly inhibits diverse strains of SARS-CoV-2 as this virus will continue to generate new variants that can potentially evade vaccine mediate immune responses," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos. "The rapid advancement of ALG-097558 as a protease inhibitor that has potent activity against a wide range of coronaviruses highlights our internal and our KU Leuven collaborators' expertise in small molecule development for antiviral indications." ALG-097558 has shown superior potency compared to nirmatrelvir against SARS-CoV-2 and multiple resistant variants in all cell-based assays tested to date. ALG-097558 is 9 to 20-fold more active than nirmatrelvir, depending on the variant. Evaluation against the Omicron variant demonstrates a 10-fold improvement in cell-based potency for ALG-097558 compared to nirmatrelvir. ALG-097558 exerts potent broad spectrum activity against alpha and beta coronaviruses, and its highly conserved target site indicates a high probability that it will retain potent activity against potential future SARS-CoV-2 variants. Projected efficacious doses of ALG-097558 can be achieved in humans without ritonavir boosting. Aligos expects to file a Phase 1 clinical trial application in 2H 2022.

08:12 EDT Huntington Ingalls releases Odyssey solutions suite - HII announced the launch of Odyssey, a suite of advanced autonomy solutions that can turn any ship or vehicle in any domain into an intelligent, robotic platform. Odyssey capabilities include multi-vehicle collaborative autonomy, autonomous health monitoring, sensor fusion and perception. The use and applications of unmanned systems are increasing worldwide, performing repetitive and dangerous tasks so humans can focus on the greater mission. Odyssey is currently integrated on naval prototypes under development and has been fielded for more than 6,000 hours on 23 vessel types.

08:11 EDT Achilles Therapeutics to host KOL webcast highlighting TRACERx study - Achilles Therapeutics announced that the Company will host a key opinion leader webcast to discuss the importance and unique utility of the TRACERx study in validating the identification of clonal neoantigens as targets for personalized T cell therapies and to highlight selections from the 31 posters and presentations on the TRACERx study presented at the 2022 American Association for Cancer Research Annual Meeting. Event details: Date: Thursday, April 14, 2022; Time: 10:30am ET / 3:30pm UK.

08:11 EDT PhaseBio: primary reversal endpoint in achieved bentracimab Phase 2b trial - PhaseBio Pharmaceuticals announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology's 71st Annual Scientific Session . The Phase 2b trial was a multi-center, randomized, double-blind, placebo-controlled study, which enrolled a total of 205 older volunteers , with 154 subjects receiving bentracimab and 51 subjects receiving placebo, after all were pretreated with dual antiplatelet therapy composed of ticagrelor and low-dose aspirin. The Phase 2b pivotal trial was conducted concurrently with the company's ongoing REVERSE-IT Phase 3 pivotal trial of bentracimab, as agreed upon with the U.S. Food and Drug Administration following an End-of-Phase 1 meeting in July 2019. Bentracimab is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in patients presenting with uncontrolled bleeding or in need of surgery. The primary efficacy endpoint for the Phase 2b trial was reversal of ticagrelor's inhibition of platelet function in actively treated subjects versus placebo as measured using the point-of-care VerifyNow PRUTest platelet function assay VerifyNow. In the Phase 2b trial, bentracimab significantly restored platelet function within five minutes of administration , as measured by multiple assays including VerifyNow. The reversal results were tightly correlated across all assays used in the study to measure platelet function. VerifyNow is also the primary measurement used to evaluate efficacy in the ongoing REVERSE-IT Phase 3 trial. There were no drug-related serious adverse events or thrombotic events reported in the Phase 2b trial. Overall, bentracimab appeared well tolerated, with subjects reporting only non-serious adverse events. The most-commonly reported adverse events were injection site bruising and headache, with similar rates seen in both the placebo and active-treatment arms. There was no significant difference between bentracimab and placebo for any of the adverse events reported. "The positive data from this Phase 2b trial of bentracimab build on the prior results that have already been published in the New England Journal of Medicine and NEJM Evidence," said Deepak L. Bhatt, M.D., MPH, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. "Based on these data, and the other clinical results we have seen to date, bentracimab appears to be a promising option for ticagrelor reversal once it is hopefully approved." T

08:10 EDT Gaming and Leisure Properties completes sale leaseback transaction with Bally's - Gaming and Leisure Properties (GLPI) announced today that, on April 1, 2022, it completed the previously announced acquisition from Bally's Corporation (BALY) of the land and real estate assets of Bally's three Black Hawk Casinos in Black Hawk, CO and Bally's Quad Cities Casino & Hotel in Rock Island, IL for $150M in total consideration. These properties were added to the existing Bally's Master Lease. The initial rent for the lease was increased by $12M on an annual basis, subject to contractual escalations based on the Consumer Price Index, with a 1% floor and 2% ceiling, subject to CPI meeting a 0.5% threshold.

08:09 EDT AMD announces agreement to acquire Pensando for $1.9B - AMD announced a definitive agreement to acquire Pensando for approximately $1.9B before working capital and other adjustments. Pensando's distributed services platform includes a high-performance, fully programmable packet processor and comprehensive software stack that accelerate networking, security, storage and other services for cloud, enterprise and edge applications. Pensando's products are already deployed at scale across cloud and enterprise customers. CEO Prem Jain and the Pensando team will join AMD as part of the Data Center Solutions Group, led by AMD Senior Vice President and General Manager Forrest Norrod. Pensando will remain focused on executing their product and technology roadmaps, now with additional scale to accelerate their business and address growing market opportunities across a broader number of customers. The acquisition is expected to close in the second quarter of 2022, following satisfaction of customary closing conditions including approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

08:07 EDT Rush Street Interactive launches BetRivers online casino, sportsbook in Ontario - Rush Street Interactive announced that its BetRivers online casino and sportsbook are live in Ontario, Canada. Eligible players aged 19 and older across the province can sign-up now and begin wagering at BetRivers.ca and on the BetRivers mobile applications.

08:07 EDT Apollo Hybrid Value raises $4.6B for second flagship fund - Apollo announced that its Hybrid Value business has closed its second flagship fund, Apollo Hybrid Value Fund II, raising approximately $4.6 billion. The fund received strong support from both new and existing limited partners committing to the all-weather strategy, which seeks to provide flexible equity and debt capital solutions to companies. HVF II's $4.6 billion in commitments is an increase of more than 40% over Hybrid Value Fund I, which raised $3.3 billion in 2019. The Hybrid Value team's strong focus on structuring capital preservation, attractive yield, and equity upside has made the strategy particularly attractive to insurance companies, sovereign wealth funds, pension funds, endowments and other institutional clients and high-net-worth individuals. Hybrid strategies were a key strategic growth area for Apollo as presented at its 2021 Investor Day.

08:05 EDT Shift4 Payments, Ontario International Airport announce partnership - Ontario International Airport announced a strategic partnership with Shift4 to implement the company's VenueNext mobile point-of-sale solution at the airport. The state-of-the-art service enables ONT customers to order and pay for food, beverages and merchandise from the convenience of their phones, allowing travelers to enjoy the growing variety of airport dining and retail options with as much - or as little - personal interaction as they want.

08:04 EDT Kratos appoints Robert Winkler as VP, corporate development, national security - Kratos Defense & Security Solutions announced that Robert Winkler, former Professional Staff Member for the U.S. Senate Committee on Armed Services and staff-lead for the Air Land Subcommittee, has joined Kratos as Vice President of Corporate Development & National Security Programs. In this role, Winkler will focus on developing strategies for aligning Kratos' development efforts with U.S. Department of Defense, Congressional, and Executive Branch priorities, as well as communicating the value of Kratos' low-cost, high-performance technology, solutions, and breakthroughs to national defense and governmental leaders.

08:04 EDT Amedisys completes acquisition of Evolution Health - Amedisys has closed on its acquisition of Evolution Health, a provider of home health services. Evolution Health, a division of Envision Healthcare, is doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati in 15 locations across Texas, Oklahoma and Ohio. Amedisys has acquired 100% of the ownership interests in Evolution Health. "By continuing the great care provided by Guardian Healthcare, Gem City, and Care Connection of Cincinnati, Amedisys can now offer both home health and hospice services in more communities across Texas, Oklahoma and Ohio," said Amedisys President and Chief Operating Officer Chris Gerard. "Amedisys is proud to expand its presence in these healthcare communities and provide more comprehensive care by aligning with our Amedisys Hospice footprint in these markets." Amedisys' home health operations now include 350 care centers in 34 states and the District of Columbia, with an average daily census of approximately 74,000 patients and approximately 11,000 home health employees.

08:03 EDT H2O Innovation renews, expands operation, maintenance contract - H2O Innovation is proud to announce that it has recently renewed the contract with its largest operation and maintenance customer, the City of Gulfport, Mississippi. This renewal, valued at $13.9 M/year, includes a scope expansion for solid waste collection and fleet management as well as annual consumer price index adjustments. The expanded four-year contract, valued at $55.5 M, brings the Corporation's O&M backlog to $131.0 M. The City also has the option to extend the contract up to four additional renewal periods of two years each, potentially lengthening the total contract term to 12 years.

08:02 EDT Porch Group closes RWS acquisition for $33M in stock, cash transaction - Porch Group successfully completed its previously announced acquisition of the home warranty and inspection software and services businesses from Residential Warranty Services, RWS, on April 1, 2022. The acquisition further enhances Porch's ability to add value to home inspectors and enhances full home warranty capabilities. The acquired businesses provide customer relationship management, CRM, software, recall check software and a unique 90-day warranty product through more than 1,000 home inspection companies. RWS distributes annual home warranty products through a nationwide network of real estate agents. Total consideration in the transaction is $33M, including $29M of cash, $4M of Porch common stock and additional contingent consideration tied to the performance of a recently launched business line. "We have worked with the RWS team for many years and their addition to Porch greatly bolsters our leadership position in the strategic home inspection industry," said Matt Ehrlichman, Founder, Chairman and CEO. "Over the last several quarters, we have realized rapid growth through the expansion of our service offerings, and RWS accelerates our warranty business and strategy. RWS inspection and warranty products strategically align with Porch's offerings, giving us confidence in our ability to drive growth in 2022 and beyond."

07:55 EDT A2Z Smart Technologies says all resolutions passed at Shareholders Meeting - A2Z Smart Technologies Corp. announced that at the Company's Annual and Special General Meeting, held on March 28, 2022 in Toronto, all resolutions were duly passed by shareholders, including a rolling 10% stock option plan and the approval of the restricted share unit plan and increase the number of restricted share units under the RSU Plan by an additional 471,716 to 2,696,047.

07:52 EDT Starbucks drops after returning CEO Schultz suspends buyback - Shares of Starbucks are falling in premarket trading after Howard Schultz, who's returning as Chief Executive Officer today, announced the suspension of the company's share buyback program. "This decision will allow us to invest more into our people and our stores - the only way to create long-term value for all stakeholders," Schultz said in a letter to employees. "Our vision is to once again reimagine a first-of-a-kind for-purpose company in which the value we create for each of us as partners, for each of us as customers, for our communities, for the planet, for shareholders - comes because our company is designed to share success with each of us and for the collective success of all our stakeholders," he wrote.

07:36 EDT CME Group reports March ADV up 12% to 24.4M contracts - CME Group reported its Q1 and March 2022 market statistics, showing average daily volume increased 19% to 26M contracts during the first quarter. March ADV increased 12% to 24.4M contracts during the month.

07:35 EDT FDA extends review timeline for Alnylam's vutrisiran NDA to treat ATTR amyloidos - Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration FDA has extended the review timeline of the New Drug Application NDA for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated, ATTR , amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and labeling facility the Company planned to use for the vutrisiran launch was recently inspected and the inspection requires classification for the FDA to take action on the vutrisiran NDA. The inspection observations were not directly related to vutrisiran. In order to minimize delays to approval, Alnylam has identified a new facility to pack and label vutrisiran and submitted an amendment to the NDA for review by the FDA. The updated Prescription Drug User Fee Act PDUFA goal date to allow for this review is July 14, 2022. No additional clinical data have been requested by the FDA. "We are committed to working with the FDA and the new facility to bring this important treatment option as quickly as possible to patients living with the polyneuropathy of hATTR amyloidosis, an inherited, progressively debilitating, and fatal disease," said Pushkal Garg, M.D., Chief Medical Officer & EVP, Development and Medical Affairs. "We are confident in our regulatory application and the body of data supporting the efficacy and safety of vutrisiran." Vutrisiran is also under review by the European Medicines Agency EMA, the Brazilian Health Regulatory Agency ANVISA and the Japanese Pharmaceuticals and Medical Devices Agency PMDA. We aim to minimize the impact of this issue on these reviews through timely resolution of the matter or utilization of an alternative facility for one or more of these regions. Vutrisiran has been granted Orphan Drug Designation in the U.S. and the European Union EU for the treatment of ATTR amyloidosis, and in Japan for transthyretin type familial amyloidosis with polyneuropathy.

07:34 EDT NextEra Energy Partners completes sale of Monument Pipeline to ARM - NextEra Energy Partners announced that it has completed the sale of Monument Pipeline, LP, an approximately 156-mile, 16-inch pipeline that transports natural gas in Texas, to ARM Monument Intermediate Holdings, an affiliate of ARM Energy Holdings, for a total consideration of approximately $203M. The Monument Pipeline was part of NextEra Energy Partners' Texas pipelines portfolio. NextEra Energy Partners continues to expect Dec. 31, 2022, run-rate adjusted EBITDA and cash available for distribution expectation ranges of $1.775B-$1.975B and $675M-$765M, respectively, reflecting calendar year 2023 expectations for the forecasted portfolio at year-end 2022. From a base of its fourth-quarter 2021 distribution per common unit at an annualized rate of $2.83 per common unit, NextEra Energy Partners continues to expect 12%-15% per year growth in limited partner distributions as being a reasonable range of expectations through at least 2024, subject to the usual caveats. NextEra Energy Partners expects the annualized rate of the fourth-quarter 2022 distribution, which is payable in February 2023, to be in a range of $3.17-$3.25 per common unit.

07:32 EDT AnPac Bio granted Nasdaq hearing for continued listing, scheduled for late April - AnPac Bio-Medical Science announced that on April 1, 2022, the Company received a Nasdaq Hearing Instructions letter from the Nasdaq Stock Market notifying the Company that a Nasdaq Hearings Panel will consider the Company's appeal at an oral hearing which will be held on April 28, 2022. On March 31, 2022, the Company filed a request for an appeal hearing before a Nasdaq Hearings Panel to present its plan to regain compliance with the applicable listing requirements of Nasdaq. This is a follow-up to its recent receipt of a Staff Determination letter dated March 24, 2022 from the Listing Qualifications Department of Nasdaq notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Global Market due to its failure to regain compliance with the minimum $50,000,000 Market Value of Listed Securities required for continued listing as set forth in Listing Rule 5450(b)(2)(A), following the 180 calendar day compliance period. The Letter also indicated that the Company has not met the minimum standard requirements of $10,000,000 in stockholders' equity, $50,000,000 in total assets and $50,000,000 in total revenue. Pursuant to the Staff Determination Letter, unless the Company requests an appeal, trading of the Company's American Depositary Shares will be suspended at the opening of business on April 4, 2022, and Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq. The April 1, 2022 Letter from Nasdaq notified the Company that because the Company had appealed, the delisting action has been temporarily stopped, pending a final written decision by the Nasdaq Hearings Panel. At the hearing, the Company must demonstrate its ability to regain compliance with the particular deficiencies cited by Nasdaq, as well as its ability to sustain long-term compliance with all applicable maintenance criteria. If the Company is currently subject to a Listing Rule compliance period for a deficiency distinct from those that are bases for Nasdaq's determination to delist the Company, it must also address its plan for regaining compliance with that particular standard within the applicable compliance period. The Company will be notified if Nasdaq identifies new deficiencies either before or after the hearing, and will be provided an opportunity to respond.

07:32 EDT Hertz, Polestar partner to accelerate electric vehicle adoption - Hertz (HTZ) and Polestar, the Swedish premium electric performance car maker, announced a new global partnership that includes purchasing up to 65,000 electric vehicles over five years. Availability is expected to begin in Spring 2022 in Europe and late 2022 in North America and Australia. For Hertz, the partnership is part of the company's ongoing commitment to lead in electrification, shared mobility and a digital-first customer experience. The partnership with Polestar builds on Hertz's announcement last October to offer its customers the largest EV rental fleet in North America and one of the largest in the world. In addition to making the fleet available to its business and leisure customers, Hertz is extending EVs to rideshare drivers as a way to further accelerate electrification. Polestar previously announced its intention to list on Nasdaq New York in a proposed business combination with Gores Guggenheim (GGPI), which is expected to close in the second quarter.

07:26 EDT Elite Pharmaceuticals, Praxgen receive FDA approval for generic doxycycline - Elite Pharmaceuticals announced that together with Elite's co-development partner, Praxgen Pharmaceuticals received approval from the US Food and Drug Administration for doxycycline hyclate 100 mg tablets. Doxycycline hyclate is an antibiotic that is used to treat a wide variety of bacterial infections.

07:23 EDT K92 Mining files technical report for Kora, Maiden Judd resource estimates - K92 Mining announces that it has filed a technical report containing an updated resource estimate on the Kora gold deposit and a maiden resource estimate on the Judd deposit, in Papua New Guinea. The Technical Report, titled, "Independent Technical Report Mineral Resource Estimate Update Kora and Judd Gold Deposits, Kainantu Project, Papua New Guinea" dated March 31, 2022, with an effective date of January 20, 2022, was prepared by Andrew Kohler, PGCert, MAIG, Simon Tear BSc, EurGeol, PGeo IGI, EurGeol, and Anthony Woodward BSc, M.Sc., MAIG. Refer to the Company's news release dated February 23, 2022, for a summary of the key results, assumptions and estimates contained in the Technical Report.

07:21 EDT Solaris Resources reports assay results from Warintza Project - Solaris Resources is pleased to report assay results from a series of additional holes from mineral resource growth drilling at its Warintza Project in southeastern Ecuador. Highlights: Additional drilling has expanded the growing northeast extension area, which remains open with follow-up and step-out drilling underway. This zone is characterized by near surface, high-grade mineralization, as detailed below, at the northeastern limit of drilling at Warintza Central and represents a priority target for further growth. SLS-54 was collared at the northeastern limit of the grid and drilled into an open volume near surface, returning 356m of 0.73% CuEq from 50m depth within a broader interval of 1,093m of 0.56% CuEq from surface This follows from near surface, high-grade mineralization previously reported from: SLS-49 - 396m of 0.70% CuEq from 50m depth within 817m of 0.60% CuEq; SLS-48 - 100m of 1.64% CuEq from 50m depth within 852m of 0.56% CuEq; SLS-42 - 740m of 0.60% CuEq from 52m depth within 906m of 0.53% CuEq; SLS-38 - 244m of 0.70% CuEq from 58m depth within 822m of 0.35% CuEq; SLS-34 - 242m of 0.67% CuEq from 52m depth within 660m of 0.47% CuEq; SLS-32 - 372m of 0.64% CuEq from 46m depth within 618m of 0.48% CuEq. Follow-up drilling from existing platforms is underway, with a 260m northeast step-out platform recently completed and a second platform stepping out further to the northeast under construction; Additional drilling has expanded the growing southeast extension area, which remains open in near surface, high-grade mineralization. SLS-52 was collared on the eastern side of the grid and drilled southeast into an open volume near surface, returning 482m of 0.62% CuEq from 96m depth, within a broader interval of 977m of 0.45% CuEq from near surface that infilled drilling at depth; SLS-53 was collared from a southeastern platform and drilled south into an open volume near surface, returning 176m of 0.78% CuEq from 16m depth, within a broader interval of 957m of 0.46% CuEq from 10m depth that infilled drilling at depth. This follows from near surface, high-grade mineralization previously reported from: SLS-45 - 236m of 0.56% CuEq from 44m depth within 564m of 0.41% CuEq; SLS-39 - 368m of 0.73% CuEq from 90m depth within 915m of 0.56% CuEq; SLS-35 - 326m of 0.80% CuEq from 50m depth within 920m of 0.62% CuEq. Additional platform construction to support follow-up and step-out drilling to test the further southeast extension of near surface, high-grade mineralization is planned, following the release of the updated mineral resource estimate. SLS-51 was collared from the south-central portion of the grid and drilled east into an open volume at surface, returning 918m of 0.50% CuEq from 130m depth within a broader interval of 1,012m of 0.47% CuEq from near surface that infilled drilling at depth. Updated Warintza Central Mineral Resource Estimate expected to be issued in April. To date, 62 holes have been completed at Warintza Central with assays reported for 54 of these. Mr. Jorge Fierro, Vice President, Exploration, commented: "These final holes expand on two key growth areas with near surface, high-grade mineralization on the edge of resource drilling that remains open. These holes will be included in the forthcoming resource update; further extensions to the northeast and southeast represent priority targets for further growth with step-out drilling commencing shortly."

07:19 EDT Howard Hughes acquires minority stake in Jean-Georges Restaurants - Howard Hughes and chef Jean-Georges Vongerichten, announced that HHC has invested $55M in Jean-Georges Restaurants to acquire a minority stake in the company and to fund growth capital for Jean-Georges' expanding global business. HHC will have the right to acquire an additional ownership stake in the company. The existing Jean-Georges Restaurants management team will retain control of all day-to-day decision making. Jean-Georges Restaurants currently has over 40 hospitality offerings and a strong pipeline of new concepts.

07:17 EDT ADC Therapeutics receives permanent J-code for Zynlonta from CMS - ADC Therapeutics announced that a permanent J-code, J9359, has been issued for Zynlonta by the U.S. Centers for Medicare & Medicaid Services, or CMS, effective as of April 1.

07:14 EDT Digihost expects to increase hashrate to 1.5 EH/s in 2022 - In 2021, Digihost operated at an average hashrate of approximately 275PH, producing an adjusted EBITDA of $14.01 million in the process. The Company anticipates a 1.5 EH/s average hashrate in 2022 which is approximately 5.5 times the Digihost's average hashrate in 2021. Over 90% of the energy consumed by the Company in its BTC mining operations is received from sources that create zero carbon emissions.

07:13 EDT Comfort Systems acquires S.C.-based acquired Atlantic Electric, no terms - Comfort Systems announced that it has acquired Atlantic Electric , and its related subsidiary headquartered in Charleston, South Carolina, and with operations in South Carolina and Western North Carolina. Atlantic was founded in 1969 and performs electrical contracting for customers in various South Carolina markets, as well as installation of airport runway lighting in the Southeast. Initially, Atlantic is expected to contribute annualized revenues of approximately $50 M and earnings before interest, taxes, depreciation, and amortization of approximately $5M. Brian Lane, Comfort Systems USA's Chief Executive Officer, commented, "Atlantic Electric and its affiliated companies bring us well-established reputations and capabilities in important Carolina markets, as well as expertise in industrial markets including runway lighting capabilities across the Southeast." Lee Richardson and Mike Richardson, President and Vice President of Atlantic Electric commented, "Choosing to join the Comfort Systems USA team was an easy decision for us, especially given the strong cultural fit, safety emphasis, and commitment to training. We believe this partnership will enhance our commitment and investment in our people and allow us to better serve our customers and communities. We feel confident in a bright future together." Considering the required amortization expense related to intangibles and other costs associated with the transaction, the acquisition is expected to make a neutral to slightly accretive contribution to earnings per share in 2022 and 2023.

07:12 EDT Digihost mines 75.24 BTC in March, 186.83 BTC in Q1 - Digihost Technology provides unaudited BTC production results for the month and quarter ended March 31, 2022 combined with an update on the Company's operations. "Throughout the first quarter of 2022, the Company continued to make progress on the deployment of the 10,600 M30S and M30S+ miners we acquired last year," said Michel Amar, Chairman and CEO of Digihost. "With more than half of those miners currently in operation we have more than doubled our hashrate from 415 PH at year-end 2021 to approximately 1 EH/s today, which at current network difficulty equates to approximately 4.25 coins per day on a run rate of over 120 coins mined per month. I am also pleased to announce to our shareholders that Digihost has adopted a new dividend policy pursuant to which the Company expects to declare future dividends that will be based upon our net income." Production Highlights for March 2022: Mined 75.24 BTC during the month, increasing total holdings to 797.47 BTC; Ethereum holdings of 1,000.89 ETH; Total digital asset inventory value consisting of BTC and ETH of approximately $39.6M as of March 31, 2022. Year-Over-Year Quarterly Comparison: The Company mined approximately 81.57 more BTC in Q1 2022, compared to Q1 2021, representing an increase of approximately 78%. Using the March 31, 2022 and March 31, 2021 closing BTC prices, the value of the Company's BTC mined in Q1 2022 increased by approximately $2.3 million, or 37% compared to Q1 2021.

07:10 EDT Red Cat secures purchase order for drone units from NATO member country - Red Cat announces that its subsidiary Teal Drones has secured an order for 15 Golden Eagle drone units, plus spares and training, from a NATO, North Atlantic Treaty Organization, member country that has committed them to deployment in the Ukraine. "Red Cat Holdings stands by Ukraine, and we will continue to support its needs to the greatest extent possible using Teal's Golden Eagle platform," added Jeff Thompson, Red Cat's CEO. "Since the war in Ukraine began, we have seen strong interest in the Teal drone platform from numerous European countries. Defense budgets within Europe have risen seemingly overnight due to the need to support this current invasion, as well as the desire to be prepared for future geopolitical conflicts. Many countries and military units are recognizing the strategic benefit of having an adequate baseline inventory of drone units that can be invaluable in reconnaissance and surveillance on the front lines. We believe this is the first of many relationships and purchases in the region."

07:09 EDT AE to acquire acquire SL Power Electronics rom Steel Partners for $144.5M - Advanced Energy (AEIS) announced that it has entered into a definitive agreement to acquire SL Power Electronics Corporation, a provider of customized power solutions for medical and advanced industrial applications, from Steel Partners Holdings (SPLP). The acquisition expands Advanced Energy's medical power solution offerings by adding a complementary portfolio of products and improves its ability to meet the growing needs of industrial and medical customers. "The addition of SL Power expands our offerings for industrial and medical applications," said Steve Kelley, President and CEO of Advanced Energy. "I believe SL Power's strong customer base, complementary product portfolio, and highly skilled team make it an ideal fit for Advanced Energy." Benefits include: Expands AE's addressable market in industrial and medical power supplies by over $400M. Complements AE's medical portfolio with low operating power, low emission EMI/EMC power supplies designed for use in FDA-certified Class-II and Class-III medical equipment. Pursuant to the terms of the Stock Purchase Agreement, AE will pay a base purchase price of $144.5M on a cash-free, debt-free basis and subject to a customary adjustment for working capital as of the closing. Advanced Energy expects to finance the transaction with currently available cash. For its fiscal year ending December 2021, SL Power generated $66M in revenue. The transaction has been approved by the Board of Directors of Advanced Energy. The transaction is expected to close during the second quarter of 2022 and is subject to customary closing conditions.

07:05 EDT Yamana Gold announces positive exploration results - Yamana Gold is pleased to announce an update on exploration activities at its El Penon mine, its Odyssey project at Canadian Malartic and its Wasamac project. At El Penon, positive initial drill results have been received from the early stage, developing South Deeps target located under cover and to the south of the El Penon deposit. The South Deeps area has had limited exploratory drilling in previous campaigns which were targeting shallower elevations in relation to the current exploration targets. The company believes these results have opened up a significant new near-mine area for exploration at El Penon with the potential for adding primary and secondary veins which could ultimately result in the company leveraging the higher processing capacity of the plant. At Odyssey, infill drill holes at East Gouldie further demonstrate the continuity and robustness of the known mineralization. Step out drilling continues to provide further mineralized intervals expanding on the previously disclosed intercepts 1,300 metres to the east. At Wasamac, infill drill results demonstrate a wide, robust mineralized zone, with exploration, including recent drilling at the newly discovered Wildcat South shear zone, continuing to support the strategic plan for an annual production platform of 200,000 ounces and a mine life of at least fifteen years. Near-mine exploration success has been a key driver of the company's track record of year-over-year mineral reserve replacement. Notably, mineral reserves continue to be replaced despite depletion from the open pit at Canadian Malartic, the Company's largest mine. While annually replacing mineral reserves, the company has also substantially grown mineral resources including at Canadian Malartic, where the Odyssey project's mineral resources are expected to result in future conversion to mineral reserves. The company's exploration success and track record of mineral reserve replacement and mineral resource growth provides a pathway for production growth of approximately 50% to 1,500,000 gold equivalent ounces within the ten-year outlook horizon and to meaningfully extend the production platform beyond that timeframe. Further growth beyond this level from the MARA and Suyai projects, in addition to the opportunities currently within the generative exploration portfolio provide additional upside potential to the ten-year outlook. The company will provide an overview of the identified opportunities and optionality within its existing portfolio in more depth at the upcoming Investor Day scheduled for April 5.

07:05 EDT Colliers International completes acquisitions of Colliers Italy, Antirion - Colliers (NASDAQ and TSX: CIGI) announced the completion of two previously reported acquisitions: Colliers Italy, a previously affiliated full service commercial real estate firm, and Antirion SGR S.p.A., one of the largest real estate investment management firms in Italy. Senior leadership teams at Colliers Italy and Antirion will continue to oversee operations of their respective firms and retain significant shareholdings in the businesses under Colliers' unique partnership model. Antirion will begin rebranding as Colliers Global Investors Italy at close.

07:04 EDT Ginkgo Bioworks, Microba Life Sciences announce partnership - Microba Life Sciences and Ginkgo Bioworks announced a partnership to identify single-strain, live bacteria product candidates against autoimmune diseases. The collaboration aims to build on Microba's precision approach to LBP development with an in-depth evaluation of the company's strains using Ginkgo's high throughput, automated screening capabilities. Through this partnership, Ginkgo will provide high-throughput screening for Microba's proprietary library of human microbiome-isolated strains, with the goal of improving treatment for autoimmune diseases such as lupus, psoriatic arthritis and certain autoimmune liver diseases. Microba plans to leverage Ginkgo's high-throughput anaerobic culturing, multi-omics data collection and analysis, functional bioassay screening, and media and fermentation optimization capabilities to generate data sets that may help characterize potential therapeutic and non-therapeutic uses of the strains. The initial partnership combining Microba's biobank and Ginkgo's anaerobic development capabilities is expected to run approximately two years. Microba Life Sciences plans to launch its Initial Public Offering on the Australian Securities Exchange on April 5. In connection with the partnership, Ginkgo is investing $3.5M in Microba. The IPO was fully underwritten by Canaccord Genuity and Bell Potter.

07:03 EDT Athira Pharma doses first subject in Phase 1 trial of ATH-1020 - Athira Pharma announced that the first subject has been dosed in a Phase 1 clinical trial investigating ATH-1020, an orally available, brain-penetrant small molecule for neuropsychiatric conditions. "This first-in-human study of ATH-1020, our second clinical product candidate, represents a significant milestone for Athira in the expansion of our clinical development pipeline and our first oral small molecule. Our novel approach targeting HGF/MET, and ATH-1020's unique pharmacology and mechanism of action, may be particularly well suited for potential treatment of neuropsychiatric indications, as evidenced by the compelling preclinical data we have recently presented," said Mark Litton, Ph.D., President and CEO of Athira Pharma. "We anticipate that the safety, tolerability and pharmacokinetic data from this Phase 1 study will help inform our further assessment of the potential of ATH-1020 in future clinical indications." The Phase 1 randomized, placebo-controlled, double-blind study will enroll approximately 68 healthy volunteers and include single and multiple ascending dose evaluations. The study will investigate the safety and tolerability of ATH-1020 as the primary endpoint and includes pharmacokinetic outcomes.

07:02 EDT IBI Group completes acquisition of RLC Architects - IBI Group announced that it has completed the purchase of Florida-based architectural firm, RLC Architects. RLC's diverse team of 25 professional staff will bring significant experience across the industrial, residential, commercial, education and interior architecture sectors. RLC complements IBI's existing industrial engineering and architectural business, expands its U.S. market presence and contributes to the firm's long-term growth strategy. The Acquisition demonstrates IBI's commitment to prudent and accretive growth while supporting an ongoing commitment to sustainability, given RLC's leadership in "green design" across South Florida. Founded in 1990, RLC specializes in planning and designing buildings and communities in South Florida. Seven of RLC's recently completed projects have attained LEED certification and over fifty percent of its professional staff have their LEED accreditations. RLC's focus on sustainable design and client-focused solutions will combine with IBI's focus on improving urban livability and taking action on climate change. The Acquisition builds upon IBI Group's strategic focus on growing its urban environment and infrastructure design presence in the U.S.

07:00 EDT Protalix, Chiesi announce BALANCE trial meets primary endpoint - Protalix and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici announced topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa, 1 mg/kg, administered every two weeks, compared to agalsidase beta for the treatment of Fabry disease. PRX-102 is a novel, PEGylated enzyme replacement therapy, or ERT, under development for the treatment of Fabry disease. The pivotal Phase III BALANCE clinical trial has been completed and topline results from the final analysis are now available. This is a 24-month, randomized, double-blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function that was designed to evaluate the safety and efficacy of 1 mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The study enrolled 78 patients who were previously treated with agalsidase beta for at least one year with an estimated glomerular filtration rate, or eGFR, slope at screening worse than -2 mL/min/1.73 m2/year. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. As first announced in October 2021, as part of a Type A End-of-Review meeting, the FDA, in principle, agreed that the proposed analysis of the BALANCE study demonstrating non-inferiority to agalsidase beta included in the data package for the PRX-102 biologics license application, or BLA, resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. Given the changed regulatory landscape in the United States with the full approval of agalsidase beta in March 2021, the primary analysis of the BALANCE study was changed from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. The primary endpoint of the BALANCE study compared the eGFR annualized changes between the two treatment arms in the ITT analysis set. The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta. The median of the eGFR slope in the PRX-102 arm was -2.514 mL/min/1.73 m2/year and -2.155 mL/min/1.73 m2/year in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians is -0.359 mL/min/1.73 m2/year. The prespecified non-inferiority margin was met. Topline results in the PP analysis set are consistent with the ITT results. The study population was composed of 47 males and 30 females, with a mean age of 44.3 years. The mean duration of prior treatment with agalsidase beta was approximately six years. At baseline, mean eGFR was 73.33 ml/min/1.73m2 and median eGFR was 74.51 ml/min/1.73m2; mean eGFR slope was -8.21 mL/min/1.73 m2/year and median eGFR slope was -7.32 ml/min/1.73m2/year. Forty-seven patients in the PRX-102 arm experienced at least one adverse event compared to 24 in the agalsidase beta arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm. Treatment-related adverse events were reported for 21 patients in the PRX-102 arm compared to 11 in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm. Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 patients in the PRX-102 arm used infusion premedication compared to 16 in the agalsidase beta arm. At the end of the study, only three out of 47 patients in the PRX-102 arm used infusion premedication compared to three out of 24 in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 patients in the PRX-102 arm experienced a total of 13 events compared to six patients experiencing a total of 51 events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm. Assessment of anti-PRX-102 antibodies or anti-agalsidase beta antibodies, respectively, in the study indicated that, for the PRX-102 arm, 18 patients were anti-drug antibody ADA-positive at baseline, of which 17 had neutralizing antibody activity. For the agalsidase beta arm, eight patients were ADA-positive at baseline, of which seven had neutralizing antibody activity. At the end of the two-year study, 11 patients receiving PRX-102 were ADA-positive, of which seven had neutralizing antibody activity, while in the agalsidase beta arm six were ADA-positive and all six had neutralizing antibody activity. Out of the 78 randomized patients, six patients discontinued the study: out of the five from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events; one patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths.

06:56 EDT Fluor announces JBIC investment of $110M into NuScale Power - Fluor announced that Japan Bank for International Cooperation, through Japan NuScale Innovation, a special purpose investment entity that also includes JGC Holdings Corporation and IHI Corporation, has purchased a preferred equity position in NuScale Power for $110M from Fluor and other existing NuScale investors. The transaction is based on an approximate $1.9B equity valuation for NuScale. Following the sale and the currently pending merger of NuScale with Spring Valley Acquisition Corporation, Japan NuScale Innovation is expected to hold approximately 8%-9% of NuScale. Fluor will continue to hold a majority interest in NuScale and assist in achieving full commercialization and perform work to advance the Carbon Free Power Project in Idaho

06:50 EDT Merck expands vaccines manufacturing facility located in Elkton, VA - Merck reaffirmed its commitment to enable broad equitable access to the company's HPV vaccines. To support this, the company has invested significantly in manufacturing, and recently expanded its vaccines manufacturing facility located in Elkton, VA, completing the construction of 120,000 square feet and adding 150 new jobs at the site to further increase capacity and supply of the company's human papillomavirus vaccines, following regulatory reviews and approvals. Merck expects supply of its HPV vaccines to double again between 2020-2023 as the company continues to expand capacity at existing facilities and as new facilities come online.

06:47 EDT Constellation Brands confirms proposal to move to single class stock structure - Constellation Brands has received a non-binding proposal from the Sands Family to declassify the company's common stock and transition to a single class common stock structure. The proposal contemplates that each share of Class B common stock would be converted into 1.35 shares of Class A common stock. It is expected that the Sands Family will continue to be Constellation's largest shareholder if a transaction were consummated on the terms proposed. According to information disclosed by the Sands Family, the proposal was not made in connection with any other corporate transaction. According to information disclosed by the Sands Family, the proposal brings "significant benefits that would accrue to the company and our stockholders," including by "increas[ing] market demand from investors who prefer single-class structures." Constellation's Board of Directors has established a Special Committee to evaluate the proposal. Any definitive agreement with the Sands Family with respect to the potential transaction must be approved by the Special Committee as well as the Board of Directors. In addition, pursuant to the terms of the proposal, any potential transaction would require the approval of holders of a majority of the shares of Class A common stock that do not also hold shares of Class B common stock.

06:45 EDT Freyr Battery names Oscar Brown as CFO - Freyr Battery (FREY) announced the appointment of Oscar Brown to the position of Group CFO. As CFO, Brown will report to Freyr's CEO, Tom Einar Jensen, and will be responsible for financial planning, performance, reporting, and capital markets engagement across the organization. He will assume his new position at Freyr effective immediately. Brown comes with more than 30 years of energy industry experience, having most recently been Senior Vice President of Strategy, Business Development and Supply Chain for Occidental Petroleum (OXY).

06:38 EDT Verve Therapeutics provides results from administration of ANGPTL3 base editor - Verve Therapeutics reported updated preclinical data in non-human primates showing durable and well-tolerated editing of the ANGPTL3 gene following administration of the company's ANGPTL3 base editor, supporting its potential as a treatment for atherosclerotic cardiovascular disease. In addition, the company provided an update on its sequential dosing research efforts, demonstrating that administration of a PCSK9 base editor followed by an ANGPTL3 base editor was durable and well-tolerated in NHPs. The data are being presented during an oral session at the American College of Cardiology 71st Annual Scientific Session & Expo.

06:34 EDT Henry Schein says CAO Gerald Benjamin to retire, Michael Ettinger named COO - Henry Schein announced that Gerald Benjamin plans to retire as Executive Vice President and Chief Administrative Officer, effective July 1, after 34 years with the company. Benjamin, who will also retire from Henry Schein's Board of Directors at the end of his current term in May, will remain an adviser to the company. In conjunction with Benjamin's retirement, Michael Ettinger will be promoted to Executive Vice President and COO, effective July 1, reporting to Stanley Bergman, Chairman of the Board and CEO of Henry Schein. Ettinger joined Henry Schein in 1994 and has served as Senior Vice President, Corporate & Legal Affairs and Secretary, since 2013 and Chief of Staff since 2015, responsible for the company's corporate affairs, communications, legal, compliance, regulatory, and security functions. Prior to his current position, he served as the company's General Counsel. The organizational changes announced today reflect the implementation of the company's succession plan for members of its senior corporate, shared services, and administrative teams.

06:31 EDT Sanara MedTech enters plan of merger with Precision Healing - Sanara MedTech announced that it has entered into a definitive agreement and plan of merger with Precision Healing, pursuant to which Precision Healing will merge with and into a wholly owned subsidiary of Sanara. The transaction has been approved by the boards of directors of both companies, received the requisite approval of Precision Healing stockholders and is expected to close today, subject to satisfaction of customary closing conditions. Prior to this transaction, Sanara owned 25.7% of Precision Healing on a fully diluted basis. The purchase price for this transaction consists of approximately $5.1M in stock and cash consideration, the assumption of outstanding options and warrants of Precision Healing and certain earnout obligations, valuing Precision Healing's equity at approximately $7.8M before the earnout consideration. The majority of the consideration will be paid by Sanara in stock with a limited number of non-accredited investors receiving cash. Concurrent with the closing of this transaction, Sanara is expected to enter into employment agreements with all key Precision Healing employees.

06:24 EDT Camber Energy receives noncompliance notification from NYSE - Camber Energy announced that on April 1 it received a letter from the NYSE American in response to the company's request for an extension of the date by which the company is to file outstanding financial reports. Camber Energy is not in compliance with NYSE American continued listing standards. Specifically, the company is not in compliance with Section 134 and 1101 of the NYSE American Company Guide given the company failed to timely file with the Securities and Exchange Commission the following reports: Form 10-K for the 9-month transition period ended December 31,2020; Form 10-Q for the period ended March 31, 2021; Form 10-Q for the period ended June 30, 2021 and Form 10-Q for the period ended September 30, 2021. The company intended to remedy the Filing Delinquency on or before April 1, however due to certain circumstances requested the exchange grant the company an extension of time by which to file the delayed reports. The exchange accepted the company's request and has allowed the company until May 20 to file the delayed reports. The filing delinquency will be cured via the filing of the delayed reports and the filing of the company's annual report on Form 10-K for the period ended December 31, 2021.

06:20 EDT Camtek says Q1 revenues exceeded expectations - Camtek announced that its revenues for Q1 exceeded expectations, and it expects to report first quarter revenues of approximately $77M. The company said, "Furthermore, despite the negative global geopolitical environment and a recurring outbreak of the Covid-19 in the world, the Company had a strong quarter in terms of order momentum and has received orders of more than $110 million during the first quarter of 2022. The great majority of these orders are expected to be shipped later in 2022. The orders were received from a broad range of customers and will be used for various applications such as Advanced Interconnect Packaging including DRAM, Front End, compound semiconductors and CIS."

06:16 EDT Hypebeast to dual list on Nasdaq, Hong Kong exchange through Iron Spark I merger - Hypebeast and Iron Spark I announced that they have entered into a definitive merger agreement that is expected to result in Hypebeast acquiring Iron Spark and becoming dual-listed on Nasdaq and the Hong Kong Stock Exchange. Founded in Hong Kong in 2005 as a sneaker blog by now executive director, chairman, and CEO Kevin Ma, Hypebeast now has a community of 26M social media followers and 18M monthly unique visitors to its digital platforms. Hypebeast achieved a CAGR of 34% from 2015 to 2021 in revenue growth and is expected to generate revenue of not less than $112M in the fiscal year ended March 31, largely driven by a growing audience of readers and the expansion of media brand partnerships. The merger with Iron Spark is expected to provide up to $180M in total gross proceeds and is expected to result in a pro forma equity valuation of $534M. Transaction implies a pro forma enterprise value of $353M, representing a 3.1x multiple based on FY2021E revenue of not less than $112M. Transaction will be funded by a combination of ISAA cash held in a trust account, newly issued Hypebeast ordinary shares, and proceeds from a PIPE transaction. Iron Spark public shareholders will continue to receive a 5c quarterly dividend until transaction close. Existing Hypebeast shareholders are expected to own 56.2% of the pro forma equity in the combined company. The transaction, which has been unanimously approved by the respective boards of directors of Hypebeast and Iron Spark, is subject to approval by Hypebeast shareholders, Iron Spark stockholders, and other customary closing conditions. The transaction is anticipated to close in Q3. The $13.3M PIPE includes cultural icons and visionaries, who have shown their support of Hypebeast's platform for cultural discovery. These include quarterback, cofounder, and investor Tom Brady; tennis superstar and advocate for social change Naomi Osaka; Thirty Five Ventures co-founders Kevin Durant and Rich Kleiman; professional Skateboarder and founder of Birdhouse Skateboards Tony Hawk; co-founder of Airbnb, chairman of Samara and Airbnb.org, Joe Gebbia; actor, filmmaker, and comedian Jonah Hill; Grammy award-winning artist Adam Levine; Electric Feel Ventures, led by manager Austin Rosen; South Korean Entertainment company, Record Label, and Creative Agency TheBlackLabel founded by Teddy Park; as well as investor in transformative entrepreneurs and LP programs IronGrey anchored by SeAH Group. Hypebeast's current management team of executive director, chairman, and CEO Kevin Ma and CFO Patrick Wong will remain in place upon transaction close. Iron Spark CEO Joshua Spear and former president of Nike Trevor Edwards are expected to be nominated to the combined company's board of directors.

06:14 EDT Tesla's Elon Musk takes 9.2% passive stake in Twitter

06:13 EDT BuzzFeed shuts down News app - BuzzFeed announced late Friday that it was shuttering the Buzzfeed News app. "Well, folks, today's the last day of the BuzzFeed News app. Thanks for the memories and see y'all out there," the message read. Reference Link

06:09 EDT LTC Properties acquires four-property portfolio for $52M - LTC Properties announced the acquisition of four LuxeRehab centers for approximately $52M. The properties, which are located in Texas and have a combined total of 339 beds primarily in private rooms, will be operated by Ignite Medical Resorts, a current LTC operating partner. The lease term is 10 years, with two 5-year renewal options, and contains a purchase option beginning at the end of the fifth lease year through the end of the seventh lease year. The company expects to receive rent of approximately $1M in each of the third and fourth quarters of 2022 and approximately $4.3M during 2023. Rent will increase annually beginning on the third anniversary of the lease by 2.0% to 4.0% based on the change in the Medicare Market Basket Rate. Additionally, LTC provided Ignite a working capital loan for up to $2M at 8% for first year increasing to 8.25% for the second year then increasing annually with the lease rate. The company initially funded this acquisition using its unsecured revolving line of credit and intends to use proceeds from previously announced asset sales, anticipated to close in the second quarter of 2022, to pay down its unsecured revolving line of credit.

06:07 EDT The Oncology Institute names Mihir Shah as CFO, succeeding Scott Dalgleish - The Oncology Institute of Hope and Innovation announced the appointment of Mihir Shah as CFO, effective immediately. In this role, Shah will lead the Accounting, Finance, Revenue Cycle Management, and Investor Relations functions, playing a key role in driving TOI's public company success and executing the strategic growth plan. Shah succeeds Scott Dalgleish, who will serve as a senior advisor through a transition period. Most recently Shah served as CFO for Commonwealth Care Alliance.

06:06 EDT Novartis integrating Pharmaceuticals, Oncology business units

06:04 EDT Atotech says exposure to Ukraine and Russia 'immaterial to operations' - Atotech noted that its direct exposure to Ukraine and Russia is immaterial to operations and financial results, and is expected to be immaterial on a combined company basis as well. The Group does not source palladium directly from Russia or Ukraine, and the majority of its palladium is from South Africa and recycling sources. Additionally, the Group is continuing to pass the cost of palladium on to customers in order to mitigate the impact of price volatility on the Group's results from operations.

05:38 EDT ReNew, Indian Oil and L&T to form JV to develop green hydrogen sector in India - Indian Oil, Larsen & Toubro, or L&T, and ReNew Power announced signing of binding term sheet for the formation of a joint venture, or JV, company to develop the nascent green hydrogen sector in India. The tripartite venture is a synergistic alliance that brings together the strong credentials of L&T in designing, executing, and delivering EPC projects, IndianOil's established expertise in petroleum refining along with its presence across the energy spectrum, and the expertise of ReNew in offering and developing utility-scale renewable energy solutions. Additionally, IndianOil and L&T have signed a binding term sheet to form a JV with equity participation to manufacture and sell Electrolyzers used in the production of Green Hydrogen. The planned JVs aim to enable India's transition from a grey hydrogen economy to a greener economy that increasingly manufactures hydrogen via electrolysis powered by renewable energy. The central government in February notified the Green Hydrogen policy aimed at boosting production of green hydrogen and green ammonia to help the nation become a global hub for the environmentally friendly version of the element.

05:33 EDT Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA - Regeneron (REGN) and Sanofi (SNY) announced the FDA has accepted for priority review the supplemental biologics license application, or sBLA, for Dupixent 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis, or EoE, a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow. The target action date for the FDA decision on this investigational use is August 3.

05:26 EDT TechnipFMC selected by Equinor South Korea to perform FEED for Firefly project - Technip Energies (FTI) has been selected by Equinor South Korea (EQNR) to perform a Front-End Engineering Design, or FEED, for the offshore floating wind Firefly project, located 70 kilometers offshore the East Coast of South Korea. The FEED contract covers engineering of the floating wind turbine substructures for the proposed 800 megawatts offshore wind farm. The design of the substructures will include Technip Energies' in-house floater technology INO15. With a capacity of 15 megawatts, INO15 technology is a three columns semi-submersible floater which is suited for fabrication in large series. The substructure design is in alignment with Equinor's wind semi design principles. Firefly wind farm is planned for an area of 2 x 75 km2 off the coast of the city of Ulsan in South Korea and will serve to feed the Korean grid. It is planned to be in operation in 2027.

05:22 EDT Weidai comments on unusual market activity - Weidai issued the following statement in light of the unusual trading activity related to the American depositary shares of the company on the New York Stock Exchange on April 1. The company said, "Normally, Weidai does not comment on market activity or rumors. However, Weidai confirms that it is not aware of any undisclosed material change or development in its business and operations or rumors in the market that would account for the recent increase in trading activity, and related increase in trading price, of its ADSs on the NYSE."

05:16 EDT Paysafe supports Ontario iGaming operators including PointsBet, Penn National - Paysafe (PSFE) has announced that it is live and supporting private iGaming operators with payments in the Canadian province of Ontario's expanded market, which has now launched. Building on longstanding payments partnerships with the Canadian provincial government-operated lotteries, Paysafe is now powering payments for operators in Ontario's new private market. Among others, these partners include PointsBet (PBTHF) and theScore Bet, a wholly-owned subsidiary of Penn National (PENN).

05:09 EDT The Very Good Food Company terminates CEO Mitchell Scott - The Very Good Food Company announced that Mitchell Scott's employment as CEO has been terminated effective immediately. The company also announced that James Davison has resigned as chief research and development officer and as a member of the board of directors as of April 1. In lieu of immediately filling the role of CEO, Very Good has temporarily created an executive committee consisting of senior executives from within the company. The executive committee structure will be used by the organization to review and approve organizational, financial, operational and strategic decisions for the company. A search for a new CEO is being initiated by the nomination committee with the help of a Vancouver-based recruiting agency.

04:55 EDT Matador to replace Camden Property in S&P 400 at open on 4/4

04:55 EDT Embecta to replace Barnes & Noble Education in S&P 600 at open on 4/4 - Becton Dickinson (BDX) is spinning off Embecta (EMBC) in a transaction expected to be completed on April 1. Post spin-off, Becton Dickinson will remain in the S&P 500. Barnes & Noble Education is no longer representative of the small-cap market space.